<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">34659259</PMID><DateCompleted><Year>2021</Year><Month>11</Month><Day>03</Day></DateCompleted><DateRevised><Year>2023</Year><Month>11</Month><Day>07</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">1664-3224</ISSN><JournalIssue CitedMedium="Internet"><Volume>12</Volume><PubDate><Year>2021</Year></PubDate></JournalIssue><Title>Frontiers in immunology</Title><ISOAbbreviation>Front Immunol</ISOAbbreviation></Journal><ArticleTitle>Beyond Vaccines: Clinical Status of Prospective COVID-19 Therapeutics.</ArticleTitle><Pagination><StartPage>752227</StartPage><MedlinePgn>752227</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">752227</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3389/fimmu.2021.752227</ELocationID><Abstract><AbstractText>Since November 2019 the SARS-CoV-2 pandemic has caused nearly 200 million infection and more than 4 million deaths globally (Updated information from the World Health Organization, as on 2<sup>nd</sup> Aug 2021). Within only one year into the pandemic, several vaccines were designed and reached approval for the immunization of the world population. The remarkable protective effects of the manufactured vaccines are demonstrated in countries with high vaccination rates, such as Israel and UK. However, limited production capacities, poor distribution infrastructures and political hesitations still hamper the availability of vaccines in many countries. In addition, due to the emergency of SARS-CoV-2 variants with immune escape properties towards the vaccines the global numbers of new infections as well as patients developing severe COVID-19, remains high. New studies reported that about 8% of infected individuals develop long term symptoms with strong personal restrictions on private as well as professional level, which contributes to the long socioeconomic problems caused by this pandemic. Until today, emergency use-approved treatment options for COVID-19 are limited to the antiviral Remdesivir, a nucleoside analogue targeting the viral polymerase, the glucocorticosteroide Dexamethasone as well as neutralizing antibodies. The therapeutic benefits of these treatments are under ongoing debate and clinical studies assessing the efficiency of these treatments are still underway. To identify new therapeutic treatments for COVID-19, now and by the post-pandemic era, diverse experimental approaches are under scientific evaluation in companies and scientific research teams all over the world. To accelerate clinical translation of promising candidates, repurposing approaches of known approved drugs are specifically fostered but also novel technologies are being developed and are under investigation. This review summarizes the recent developments from the lab bench as well as the clinical status of emerging therapeutic candidates and discusses possible therapeutic entry points for the treatment strategies with regard to the biology of SARS-CoV-2 and the clinical course of COVID-19.</AbstractText><CopyrightInformation>Copyright &#xa9; 2021 Kumar, &#xc7;al&#x131;&#x15f;kan, Janowski, Faist, Conrad, Lange, Ludwig and Brunotte.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kumar</LastName><ForeName>Sriram</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Institute of Virology, University of M&#xfc;nster, M&#xfc;nster, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>EvoPAD Research Training Group 2220, University of M&#xfc;nster, M&#xfc;nster, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>&#xc7;al&#x131;&#x15f;kan</LastName><ForeName>Duygu Merve</ForeName><Initials>DM</Initials><AffiliationInfo><Affiliation>Institute of Virology, University of M&#xfc;nster, M&#xfc;nster, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>EvoPAD Research Training Group 2220, University of M&#xfc;nster, M&#xfc;nster, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Janowski</LastName><ForeName>Josua</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Institute of Virology, University of M&#xfc;nster, M&#xfc;nster, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>SP BioSciences Graduate Program, University of M&#xfc;nster, M&#xfc;nster, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Faist</LastName><ForeName>Aileen</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Institute of Virology, University of M&#xfc;nster, M&#xfc;nster, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>CiM-IMPRS Graduate Program, University of M&#xfc;nster, M&#xfc;nster, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Conrad</LastName><ForeName>Beate Claudine Gisela</ForeName><Initials>BCG</Initials><AffiliationInfo><Affiliation>Institute of Virology, University of M&#xfc;nster, M&#xfc;nster, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lange</LastName><ForeName>Julius</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Institute of Virology, University of M&#xfc;nster, M&#xfc;nster, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ludwig</LastName><ForeName>Stephan</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Institute of Virology, University of M&#xfc;nster, M&#xfc;nster, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>EvoPAD Research Training Group 2220, University of M&#xfc;nster, M&#xfc;nster, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>CiM-IMPRS Graduate Program, University of M&#xfc;nster, M&#xfc;nster, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Interdisciplinary Centre for Medical Research, University of M&#xfc;nster, M&#xfc;nster, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brunotte</LastName><ForeName>Linda</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Institute of Virology, University of M&#xfc;nster, M&#xfc;nster, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Interdisciplinary Centre for Medical Research, University of M&#xfc;nster, M&#xfc;nster, Germany.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>10</Month><Day>01</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Front Immunol</MedlineTA><NlmUniqueID>101560960</NlmUniqueID><ISSNLinking>1664-3224</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000911">Antibodies, Monoclonal</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000086663">COVID-19 Vaccines</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000911" MajorTopicYN="N">Antibodies, Monoclonal</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="N">COVID-19</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086663" MajorTopicYN="N">COVID-19 Vaccines</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014611" MajorTopicYN="N">Vaccination</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000093485" MajorTopicYN="Y">COVID-19 Drug Treatment</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">Long COVID</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword><Keyword MajorTopicYN="N">antivirals</Keyword><Keyword MajorTopicYN="N">immunomodulators</Keyword><Keyword MajorTopicYN="N">interferons</Keyword></KeywordList><CoiStatement>SL is a founder, shareholder and board member of Atriva Therapeutics GmbH, T&#xfc;bingen, Germany, a pharmaceutical company developing novel HTA against respiratory viral diseases including COVID-19. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>8</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>9</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>10</Month><Day>18</Day><Hour>8</Hour><Minute>55</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>10</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>11</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2021</Year><Month>10</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34659259</ArticleId><ArticleId IdType="pmc">PMC8519339</ArticleId><ArticleId IdType="doi">10.3389/fimmu.2021.752227</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Lai CC, Shih TP, Ko WC, Tang HJ, Hsueh PR. Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Coronavirus Disease-2019 (COVID-19): The Epidemic and the Challenges. Int J Antimicrobial Agents (2020) 55:105924. doi: 10.1016/j.ijantimicag.2020.105924</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijantimicag.2020.105924</ArticleId><ArticleId IdType="pmc">PMC7127800</ArticleId><ArticleId IdType="pubmed">32081636</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu R, Zhao X, Li J, Niu P, Yang B, Wu H, et al. . Genomic Characterisation and Epidemiology of 2019 Novel Coronavirus: Implications for Virus Origins and Receptor Binding. Lancet (2020) 395(10224):565&#x2013;74. doi: 10.1016/S0140-6736(20)30251-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(20)30251-8</ArticleId><ArticleId IdType="pmc">PMC7159086</ArticleId><ArticleId IdType="pubmed">32007145</ArticleId></ArticleIdList></Reference><Reference><Citation>Walls AC, Park YJ, Tortorici MA, Wall A, McGuire AT, Veesler D. Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein. Cell (2020) 181(2):281&#x2013;92. doi: 10.1016/j.cell.2020.02.058</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2020.02.058</ArticleId><ArticleId IdType="pmc">PMC7102599</ArticleId><ArticleId IdType="pubmed">32155444</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoffmann M, Kleine-Weber H, Schroeder S, Kr&#xfc;ger N, Herrler T, Erichsen S, et al. . SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell (2020) 181(2):271&#x2013;80. doi: 10.1016/j.cell.2020.02.052</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2020.02.052</ArticleId><ArticleId IdType="pmc">PMC7102627</ArticleId><ArticleId IdType="pubmed">32142651</ArticleId></ArticleIdList></Reference><Reference><Citation>Blaess M, Kaiser L, Sommerfeld O, Csuk R, Deigner HP. Drugs, Metabolites, and Lung Accumulating Small Lysosomotropic Molecules: Multiple Targeting Impedes Sars-Cov-2 Infection and Progress to Covid-19. Int J Mol Sci (2021) 22(4):1797. doi: 10.3390/ijms22041797</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms22041797</ArticleId><ArticleId IdType="pmc">PMC7918659</ArticleId><ArticleId IdType="pubmed">33670304</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu X, Liu Y, Weiss S, Arnold E, Sarafianos SG, Ding J. Molecular Model of SARS Coronavirus Polymerase: Implications for Biochemical Functions and Drug Design. Nucleic Acids Res (2003) 31(24):7117&#x2013;30. doi: 10.1093/nar/gkg916</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gkg916</ArticleId><ArticleId IdType="pmc">PMC291860</ArticleId><ArticleId IdType="pubmed">14654687</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu B, Guo H, Zhou P, Shi ZL. Characteristics of SARS-CoV-2 and COVID-19. Nat Rev Microbiol (2021) 19:141&#x2013;54. doi: 10.1038/s41579-020-00459-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41579-020-00459-7</ArticleId><ArticleId IdType="pmc">PMC7537588</ArticleId><ArticleId IdType="pubmed">33024307</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee IC, Huo TI, Huang YH. Gastrointestinal and Liver Manifestations in Patients With COVID-19. J Chin Med Assoc (2020) 83:521&#x2013;3. doi: 10.1097/JCMA.0000000000000319</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/JCMA.0000000000000319</ArticleId><ArticleId IdType="pmc">PMC7176263</ArticleId><ArticleId IdType="pubmed">32243269</ArticleId></ArticleIdList></Reference><Reference><Citation>Gavriatopoulou M, Korompoki E, Fotiou D, Ntanasis-Stathopoulos I, Psaltopoulou T, Kastritis E, et al. . Organ-Specific Manifestations of COVID-19 Infection. Clin Exp Med (2020) 20:493&#x2013;506. doi: 10.1007/s10238-020-00648-x</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10238-020-00648-x</ArticleId><ArticleId IdType="pmc">PMC7383117</ArticleId><ArticleId IdType="pubmed">32720223</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen T, Wu D, Chen H, Yan W, Yang D, Chen G, et al. . Clinical Characteristics of 113 Deceased Patients With Coronavirus Disease 2019: Retrospective Study. BMJ (2020) 368:m1091. doi: 10.1136/bmj.m1091</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.m1091</ArticleId><ArticleId IdType="pmc">PMC7190011</ArticleId><ArticleId IdType="pubmed">32217556</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. . Clinical Features of Patients Infected With 2019 Novel Coronavirus in Wuhan, China. Lancet (2020) 395(10223):497&#x2013;506. doi: 10.1016/S0140-6736(20)30183-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(20)30183-5</ArticleId><ArticleId IdType="pmc">PMC7159299</ArticleId><ArticleId IdType="pubmed">31986264</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo YR, Cao QD, Hong ZS, Tan YY, Chen SD, Jin HJ, et al. . The Origin, Transmission and Clinical Therapies on Coronavirus Disease 2019 (COVID-19) Outbreak- A N Update on the Status. Military Med Res (2020) 7:11. doi: 10.1186/s40779-020-00240-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40779-020-00240-0</ArticleId><ArticleId IdType="pmc">PMC7068984</ArticleId><ArticleId IdType="pubmed">32169119</ArticleId></ArticleIdList></Reference><Reference><Citation>Tang L, Yin Z, Hu Y, Mei H. Controlling Cytokine Storm Is Vital in COVID-19. Front Immunol (2020) 11. doi: 10.3389/fimmu.2020.570993</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2020.570993</ArticleId><ArticleId IdType="pmc">PMC7734084</ArticleId><ArticleId IdType="pubmed">33329533</ArticleId></ArticleIdList></Reference><Reference><Citation>Siddiqi HK, Mehra MR. COVID-19 Illness in Native and Immunosuppressed States: A Clinical&#x2013;Therapeutic Staging Proposal. J&#xa0;Heart Lung Transplant (2020) 39:405&#x2013;7. doi: 10.1016/j.healun.2020.03.012</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.healun.2020.03.012</ArticleId><ArticleId IdType="pmc">PMC7118652</ArticleId><ArticleId IdType="pubmed">32362390</ArticleId></ArticleIdList></Reference><Reference><Citation>Hamming I, Timens W, Bulthuis MLC, Lely AT, Navis GJ, van Goor H. Tissue Distribution of ACE2 Protein, the Functional Receptor for SARS Coronavirus. A First Step in Understanding SARS Pathogenesis. J Pathol (2004) 203(2):631&#x2013;7. doi: 10.1002/path.1570</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/path.1570</ArticleId><ArticleId IdType="pmc">PMC7167720</ArticleId><ArticleId IdType="pubmed">15141377</ArticleId></ArticleIdList></Reference><Reference><Citation>Ortiz ME, Thurman A, Pezzulo AA, Leidinger MR, Klesney-Tait JA, Karp PH, et al. . Heterogeneous Expression of the SARS-Coronavirus-2 Receptor ACE2 in the Human Respiratory Tract. EBioMedicine (2020) 60:102976. doi: 10.1016/j.ebiom.2020.102976</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ebiom.2020.102976</ArticleId><ArticleId IdType="pmc">PMC7505653</ArticleId><ArticleId IdType="pubmed">32971472</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen Y, Klein SL, Garibaldi BT, Li H, Wu C, Osevala NM, et al. . Aging in COVID-19: Vulnerability, Immunity and Intervention. Ageing Res Rev (2021) 65:101205. doi: 10.1016/j.arr.2020.101205</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.arr.2020.101205</ArticleId><ArticleId IdType="pmc">PMC7604159</ArticleId><ArticleId IdType="pubmed">33137510</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. . Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. JAMA - J Am Med Assoc (2020) 323(11):1061&#x2013;9. doi: 10.1001/jama.2020.1585</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2020.1585</ArticleId><ArticleId IdType="pmc">PMC7042881</ArticleId><ArticleId IdType="pubmed">32031570</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu C, Zhao Y, Okwan-Duodu D, Basho R, Cui X. COVID-19 in Cancer Patients: Risk, Clinical Features, and Management. Cancer Biol Med (2020) 17:519&#x2013;27. doi: 10.20892/j.issn.2095-3941.2020.0289</Citation><ArticleIdList><ArticleId IdType="doi">10.20892/j.issn.2095-3941.2020.0289</ArticleId><ArticleId IdType="pmc">PMC7476081</ArticleId><ArticleId IdType="pubmed">32944387</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen J, Qi T, Liu L, Ling Y, Qian Z, Li T, et al. . Clinical Progression of Patients With COVID-19 in Shanghai, China. J Infect (2020) 80(5):e1&#x2013;6. doi: 10.1016/j.jinf.2020.03.004</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jinf.2020.03.004</ArticleId><ArticleId IdType="pmc">PMC7102530</ArticleId><ArticleId IdType="pubmed">32171869</ArticleId></ArticleIdList></Reference><Reference><Citation>Nojomi M, Yassin Z, Keyvani H, Makiani MJ, Roham M, Laali A, et al. . Effect of Arbidol (Umifenovir) on COVID-19: A Randomized Controlled Trial. BMC Infect Dis (2020) 20(1):954&#x2013;64. doi: 10.1186/s12879-020-05698-w</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12879-020-05698-w</ArticleId><ArticleId IdType="pmc">PMC7734453</ArticleId><ArticleId IdType="pubmed">33317461</ArticleId></ArticleIdList></Reference><Reference><Citation>Vankadari N. Arbidol: A Potential Antiviral Drug for the Treatment of SARS-CoV-2 by Blocking Trimerization of the Spike Glycoprotein. Int J Antimicrobial Agents (2020) 56(2):105998. doi: 10.1016/j.ijantimicag.2020.105998</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijantimicag.2020.105998</ArticleId><ArticleId IdType="pmc">PMC7187825</ArticleId><ArticleId IdType="pubmed">32360231</ArticleId></ArticleIdList></Reference><Reference><Citation>Padhi AK, Seal A, Khan JM, Ahamed M, Tripathi T. Unraveling the Mechanism of Arbidol Binding and Inhibition of SARS-CoV-2: Insights From Atomistic Simulations. Eur J Pharmacol (2021) 894:173836. doi: 10.1016/j.ejphar.2020.173836</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ejphar.2020.173836</ArticleId><ArticleId IdType="pmc">PMC7773528</ArticleId><ArticleId IdType="pubmed">33387467</ArticleId></ArticleIdList></Reference><Reference><Citation>Lian N, Xie H, Lin S, Huang J, Zhao J, Lin Q. Umifenovir Treatment is Not Associated With Improved Outcomes in Patients With Coronavirus Disease 2019: A Retrospective Study. Clin Microbiol Infect (2020) 26(7):917&#x2013;21. doi: 10.1016/j.cmi.2020.04.026</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cmi.2020.04.026</ArticleId><ArticleId IdType="pmc">PMC7182750</ArticleId><ArticleId IdType="pubmed">32344167</ArticleId></ArticleIdList></Reference><Reference><Citation>Deng L, Li C, Zeng Q, Liu X, Li X, Zhang H, et al. . Arbidol Combined With LPV/r Versus LPV/r Alone Against Corona Virus Disease 2019: A Retrospective Cohort Study. J Infect (2020) 81(1):e1&#x2013;5. doi: 10.1016/j.jinf.2020.03.002</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jinf.2020.03.002</ArticleId><ArticleId IdType="pmc">PMC7156152</ArticleId><ArticleId IdType="pubmed">32171872</ArticleId></ArticleIdList></Reference><Reference><Citation>Jomah S, Asdaq SMB, Al-Yamani MJ. Clinical Efficacy of Antivirals Against Novel Coronavirus (COVID-19): A Review. J Infect Public Health (2020) 13:11871195. doi: 10.1016/j.jiph.2020.07.013</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jiph.2020.07.013</ArticleId><ArticleId IdType="pmc">PMC7396961</ArticleId><ArticleId IdType="pubmed">32773212</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang D, Yu H, Wang T, Yang H, Yao R, Liang Z. Efficacy and Safety of Umifenovir for Coronavirus Disease 2019 (COVID-19): A Systematic Review and Meta-Analysis. J Med Virol (2021) 93(1):481&#x2013;90. doi: 10.1002/jmv.26256</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.26256</ArticleId><ArticleId IdType="pmc">PMC7361300</ArticleId><ArticleId IdType="pubmed">32617989</ArticleId></ArticleIdList></Reference><Reference><Citation>Yuan S, Yin X, Meng X, Chan J, Ye Z-W, Riva L, et al. . Clofazimine is a Broad-Spectrum Coronavirus Inhibitor That Antagonizes SARS-CoV-2 Replication in Primary Human Cell Culture and Hamsters. Res Square (2020). doi: 10.21203/rs.3.rs-86169/v1</Citation><ArticleIdList><ArticleId IdType="doi">10.21203/rs.3.rs-86169/v1</ArticleId></ArticleIdList></Reference><Reference><Citation>Duan K, Liu B, Li C, Zhang H, Yu T, Qu J, et al. . Effectiveness of Convalescent Plasma Therapy in Severe COVID-19 Patients. Proc Natl Acad Sci USA (2020) 117(17):9490&#x2013;6. doi: 10.1073/pnas.2007408117</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.2007408117</ArticleId><ArticleId IdType="pmc">PMC7196837</ArticleId><ArticleId IdType="pubmed">32253318</ArticleId></ArticleIdList></Reference><Reference><Citation>Shen C, Wang Z, Zhao F, Yang Y, Li J, Yuan J, et al. . Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma. JAMA - J Am Med Assoc (2020) 323(16):1582&#x2013;9. doi: 10.1001/jama.2020.4783</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2020.4783</ArticleId><ArticleId IdType="pmc">PMC7101507</ArticleId><ArticleId IdType="pubmed">32219428</ArticleId></ArticleIdList></Reference><Reference><Citation>Ahn JY, Sohn Y, Lee SH, Cho Y, Hyun JH, Baek YJ, et al. . Use of Convalescent Plasma Therapy in Two Covid-19 Patients With Acute Respiratory Distress Syndrome in Korea. J Korean Med Sci (2020) 35(14):e149. doi: 10.3346/jkms.2020.35.e149</Citation><ArticleIdList><ArticleId IdType="doi">10.3346/jkms.2020.35.e149</ArticleId><ArticleId IdType="pmc">PMC7152526</ArticleId><ArticleId IdType="pubmed">32281317</ArticleId></ArticleIdList></Reference><Reference><Citation>Salazar E, Perez KK, Ashraf M, Chen J, Castillo B, Christensen PA, et al. . Treatment of Coronavirus Disease 2019 (COVID-19) Patients With Convalescent Plasma. Am J Pathol (2020) 190(8):1680&#x2013;90. doi: 10.1016/j.ajpath.2020.05.014</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ajpath.2020.05.014</ArticleId><ArticleId IdType="pmc">PMC7251400</ArticleId><ArticleId IdType="pubmed">32473109</ArticleId></ArticleIdList></Reference><Reference><Citation>Li L, Zhang W, Hu Y, Tong X, Zheng S, Yang J, et al. . Effect of Convalescent Plasma Therapy on Time to Clinical Improvement in Patients With Severe and Life-Threatening COVID-19: A Randomized Clinical Trial. JAMA - J Am Med Assoc (2020) 324(5):460&#x2013;70. doi: 10.1001/jama.2020.12607</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2020.12607</ArticleId><ArticleId IdType="pmc">PMC7270883</ArticleId><ArticleId IdType="pubmed">32492084</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu STH, Aberg JA. Convalescent Plasma in Patients Hospitalised With COVID-19. Lancet (2021) 397:2024&#x2013;5. doi: 10.1016/S0140-6736(21)01064-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(21)01064-3</ArticleId><ArticleId IdType="pmc">PMC8121524</ArticleId><ArticleId IdType="pubmed">34000255</ArticleId></ArticleIdList></Reference><Reference><Citation>Casadevall A, Pirofski LA. The Convalescent Sera Option for Containing COVID-19. J Clin Invest (2020) 130:1545&#x2013;8. doi: 10.1172/JCI138003</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI138003</ArticleId><ArticleId IdType="pmc">PMC7108922</ArticleId><ArticleId IdType="pubmed">32167489</ArticleId></ArticleIdList></Reference><Reference><Citation>Kemp SA, Collier DA, Datir RP, Ferreira IATM, Gayed S, Jahun A, et al. . SARS-CoV-2 Evolution During Treatment of Chronic Infection. Nature (2021) 592(7853):277&#x2013;82. doi: 10.1038/s41586-021-03291-y</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-021-03291-y</ArticleId><ArticleId IdType="pmc">PMC7610568</ArticleId><ArticleId IdType="pubmed">33545711</ArticleId></ArticleIdList></Reference><Reference><Citation>Bamlanivimab . Drugs and Lactation Database. Bethesda (MD): National Library of Medicine; (2021) (US. 2006&#x2013;2021 Apr 19 [Internet].</Citation></Reference><Reference><Citation>Etesevimab and Bamlanivimab . Drugs and Lactation Database. Bethesda (MD): National Library of Medicine; (2021) (US. 2006&#x2013;2021 Apr 19; PMID: 33630482 [Internet].</Citation></Reference><Reference><Citation>Gottlieb RL, Nirula A, Chen P, Boscia J, Heller B, Morris J, et al. . Effect of Bamlanivimab as Monotherapy or in Combination With Etesevimab on Viral Load in Patients With Mild to Moderate COVID-19: A Randomized Clinical Trial. JAMA - J Am Med Assoc (2021) 325(7):632&#x2013;44. doi: 10.1001/jama.2021.0202</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2021.0202</ArticleId><ArticleId IdType="pmc">PMC7821080</ArticleId><ArticleId IdType="pubmed">33475701</ArticleId></ArticleIdList></Reference><Reference><Citation>Baum A, Fulton BO, Wloga E, Copin R, Pascal KE, Russo V, et al. . Antibody Cocktail to SARS-CoV-2 Spike Protein Prevents Rapid Mutational Escape Seen With Individual Antibodies. Science (2020) 369(6506):1014&#x2013;8. doi: 10.1126/science.abd0831</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abd0831</ArticleId><ArticleId IdType="pmc">PMC7299283</ArticleId><ArticleId IdType="pubmed">32540904</ArticleId></ArticleIdList></Reference><Reference><Citation>Weinreich DM, Sivapalasingam S, Norton T, Ali S, Gao H, Bhore R, et al. . REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients With Covid-19. N Engl J Med (2021) 384(3):238&#x2013;51. doi: 10.1056/NEJMoa2035002</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2035002</ArticleId><ArticleId IdType="pmc">PMC7781102</ArticleId><ArticleId IdType="pubmed">33332778</ArticleId></ArticleIdList></Reference><Reference><Citation>Cathcart AL, Havenar-Daughton C, Lempp FA, Ma D, Schmid MA, Agostini ML, et al. . The Dual Function Monoclonal Antibodies VIR-7831 and VIR-7832 Demonstrate Potent In Vitro and 2 In Vivo Activity Against SARS-CoV-2 3 4 5. bioRxiv (2021). doi: 10.1101/2021.03.09.434607</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2021.03.09.434607</ArticleId></ArticleIdList></Reference><Reference><Citation>Zoufaly A, Poglitsch M, Aberle JH, Hoepler W, Seitz T, Traugott M, et al. . Human Recombinant Soluble ACE2 in Severe COVID-19. Lancet Respir Med (2020) 8(11):e78. doi: 10.1016/S2213-2600(20)30418-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2213-2600(20)30418-5</ArticleId><ArticleId IdType="pmc">PMC7515587</ArticleId><ArticleId IdType="pubmed">33131609</ArticleId></ArticleIdList></Reference><Reference><Citation>Pang X, Cui Y, Zhu Y. Recombinant Human ACE2: Potential Therapeutics of SARS-CoV-2 Infection and Its Complication. Acta Pharmacol Sin (2020) 41:1255&#x2013;7. doi: 10.1038/s41401-020-0430-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41401-020-0430-6</ArticleId><ArticleId IdType="pmc">PMC7313652</ArticleId><ArticleId IdType="pubmed">32581256</ArticleId></ArticleIdList></Reference><Reference><Citation>Monteil V, Dyczynski M, Lauschke VM, Kwon H, Wirnsberger G, Youhanna S, et al. . Human Soluble ACE2 Improves the Effect of Remdesivir in SARS-CoV-2 Infection. EMBO Mol Med (2021) 13(1):e13426. doi: 10.15252/emmm.202013426</Citation><ArticleIdList><ArticleId IdType="doi">10.15252/emmm.202013426</ArticleId><ArticleId IdType="pmc">PMC7799356</ArticleId><ArticleId IdType="pubmed">33179852</ArticleId></ArticleIdList></Reference><Reference><Citation>Rodell CB. An ACE Therapy for COVID-19. Sci Trans Med (2020) 12(541):eabb5676. doi: 10.1126/scitranslmed.abb5676</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.abb5676</ArticleId></ArticleIdList></Reference><Reference><Citation>Kruse RL. Therapeutic Strategies in an Outbreak Scenario to Treat the Novel Coronavirus Originating in Wuhan, China. F1000Research (2020) 9. doi: 10.12688/f1000research.22211.1</Citation><ArticleIdList><ArticleId IdType="doi">10.12688/f1000research.22211.1</ArticleId><ArticleId IdType="pmc">PMC7029759</ArticleId><ArticleId IdType="pubmed">32117569</ArticleId></ArticleIdList></Reference><Reference><Citation>Svilenov HL, Sacherl J, Reiter A, Wolff L, Chen CC, Wachs FP, et al. . Efficient Inhibition of SARS-CoV-2 Strains by a Novel ACE2-IgG4-Fc Fusion Protein With a Stabilized Hinge Region. bioRxiv (2020). doi: 10.1101/2020.12.06.413443</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2020.12.06.413443</ArticleId></ArticleIdList></Reference><Reference><Citation>Frediansyah A, Nainu F, Dhama K, Mudatsir M, Harapan H. Remdesivir and Its Antiviral Activity Against COVID-19: A Systematic Review. Clin Epidemiol Global Health (2021) 9:2213&#x2013;3984. doi: 10.1016/j.cegh.2020.07.011</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cegh.2020.07.011</ArticleId><ArticleId IdType="pmc">PMC7410793</ArticleId><ArticleId IdType="pubmed">32838064</ArticleId></ArticleIdList></Reference><Reference><Citation>de Wit E, Feldmann F, Cronin J, Jordan R, Okumura A, Thomas T, et al. . Prophylactic and Therapeutic Remdesivir (GS-5734) Treatment in the Rhesus Macaque Model of MERS-CoV Infection. Proc Natl Acad Sci USA (2020) 117(12):6771&#x2013;6. doi: 10.1073/pnas.1922083117</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1922083117</ArticleId><ArticleId IdType="pmc">PMC7104368</ArticleId><ArticleId IdType="pubmed">32054787</ArticleId></ArticleIdList></Reference><Reference><Citation>Holshue ML, DeBolt C, Lindquist S, Lofy KH, Wiesman J, Bruce H, et al. . First Case of 2019 Novel Coronavirus in the United States. New Engl J Med (2020) 382(10):929&#x2013;36. doi: 10.1056/NEJMoa2001191</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2001191</ArticleId><ArticleId IdType="pmc">PMC7092802</ArticleId><ArticleId IdType="pubmed">32004427</ArticleId></ArticleIdList></Reference><Reference><Citation>Pagliano P, Scarpati G, Sellitto C, Conti V, Spera AM, Ascione T, et al. . Experimental Pharmacotherapy for Covid-19: The Latest Advances. J Exp Pharmacol (2021) 13:1&#x2013;13. doi: 10.2147/JEP.S255209</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/JEP.S255209</ArticleId><ArticleId IdType="pmc">PMC7800714</ArticleId><ArticleId IdType="pubmed">33442304</ArticleId></ArticleIdList></Reference><Reference><Citation>Beigel JH, Tomashek KM, Dodd LE, Mehta AK, Zingman BS, Kalil AC, et al. . Remdesivir for the Treatment of Covid-19 &#x2014; Final Report. New Engl J Med (2020) 383(19):1813&#x2013;26. doi: 10.1056/NEJMc2022236</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMc2022236</ArticleId><ArticleId IdType="pmc">PMC7262788</ArticleId><ArticleId IdType="pubmed">32445440</ArticleId></ArticleIdList></Reference><Reference><Citation>Twomey JD, Luo S, Dean AQ, Bozza WP, Nalli A, Zhang B. COVID-19 Update: The Race to Therapeutic Development. Drug Resistance Updates (2020) 53:100733. doi: 10.1016/j.drup.2020.100733</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.drup.2020.100733</ArticleId><ArticleId IdType="pmc">PMC7584885</ArticleId><ArticleId IdType="pubmed">33161277</ArticleId></ArticleIdList></Reference><Reference><Citation>Pan H, Peto R, Karim QA, Alejandria M, Henao-Restrepo AM, Garc&#xed;a CH, et al. . Repurposed Antiviral Drugs for COVID-19 &#x2013;Interim WHO SOLIDARITY Trial Results. N Engl J Med (2020) 348(6):497&#x2013;511. doi: 10.1056/NEJMoa2023184</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2023184</ArticleId><ArticleId IdType="pmc">PMC7727327</ArticleId><ArticleId IdType="pubmed">33264556</ArticleId></ArticleIdList></Reference><Reference><Citation>Young B, Tan TT, Leo YS. The Place for Remdesivir in COVID-19 Treatment. Lancet Infect Dis (2021) 21:20&#x2013;1. doi: 10.1016/S1473-3099(20)30911-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(20)30911-7</ArticleId><ArticleId IdType="pmc">PMC7837362</ArticleId><ArticleId IdType="pubmed">33248473</ArticleId></ArticleIdList></Reference><Reference><Citation>Agrawal U, Raju R, Udwadia ZF. Favipiravir: A New and Emerging Antiviral Option in COVID-19. Med J Armed Forces India (2020) 76:370&#x2013;6. doi: 10.1016/j.mjafi.2020.08.004</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.mjafi.2020.08.004</ArticleId><ArticleId IdType="pmc">PMC7467067</ArticleId><ArticleId IdType="pubmed">32895599</ArticleId></ArticleIdList></Reference><Reference><Citation>Naesens L, Guddat LW, Keough DT, van Kuilenburg ABP, Meijer J, vande Voorde J, et al. . Role of Human Hypoxanthine Guanine Phosphoribosyltransferase in Activation of the Antiviral Agent T-705 (Favipiravir). Mol Pharmacol (2013) 84(4):615&#x2013;29. doi: 10.1124/mol.113.087247</Citation><ArticleIdList><ArticleId IdType="doi">10.1124/mol.113.087247</ArticleId><ArticleId IdType="pubmed">23907213</ArticleId></ArticleIdList></Reference><Reference><Citation>Joshi S, Parkar J, Ansari A, Vora A, Talwar D, Tiwaskar M, et al. . Role of Favipiravir in the Treatment of COVID-19. Int J Infect Dis (2021) 102:501&#x2013;8. doi: 10.1016/j.ijid.2020.10.069</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijid.2020.10.069</ArticleId><ArticleId IdType="pmc">PMC7831863</ArticleId><ArticleId IdType="pubmed">33130203</ArticleId></ArticleIdList></Reference><Reference><Citation>Kramer DG, da Silva MJL, da, Silva GSE, de, Moura AMMA, et al. . Favipiravir as a Potential Drug in the Treatment of COVID-19. Int J Res - GRANTHAALAYAH (2020) 8(4):7&#x2013;12. doi: 10.29121/granthaalayah.v8.i4.2020.2</Citation><ArticleIdList><ArticleId IdType="doi">10.29121/granthaalayah.v8.i4.2020.2</ArticleId></ArticleIdList></Reference><Reference><Citation>Kelleni MT. Tocilizumab, Remdesivir, Favipiravir, and Dexamethasone Repurposed for COVID-19: A Comprehensive Clinical and Pharmacovigilant Reassessment. SN Compr Clin Med (2021) 3(4):1&#x2013;5. doi: 10.1007/s42399-021-00824-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s42399-021-00824-4</ArticleId><ArticleId IdType="pmc">PMC7894610</ArticleId><ArticleId IdType="pubmed">33644693</ArticleId></ArticleIdList></Reference><Reference><Citation>Pilkington V, Pepperrell T, Hill A. A Review of the Safety of Favipiravir &#x2013; a Potential Treatment in the COVID-19 Pandemic? J Virus Eradication (2020) 6:45&#x2013;51. doi: 10.1016/S2055-6640(20)30016-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2055-6640(20)30016-9</ArticleId><ArticleId IdType="pmc">PMC7331506</ArticleId><ArticleId IdType="pubmed">32405421</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen C, Zhang Y, Huang J, Yin P, Cheng Z, Wu J, et al. . Favipiravir Versus Arbidol for COVID-19: A Randomized Clinical Trial. Front Pharmacol (2021) 12:683296. doi: 10.1101/2020.03.17.20037432</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2020.03.17.20037432</ArticleId><ArticleId IdType="pmc">PMC8443786</ArticleId><ArticleId IdType="pubmed">34539392</ArticleId></ArticleIdList></Reference><Reference><Citation>Cai Q, Yang M, Liu D, Chen J, Shu D, Xia J, et al. . Experimental Treatment With Favipiravir for COVID-19: An Open-Label Control Study. Engineering (2020) 6(10):1192&#x2013;8. doi: 10.1016/j.eng.2020.03.007</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.eng.2020.03.007</ArticleId><ArticleId IdType="pmc">PMC7185795</ArticleId><ArticleId IdType="pubmed">32346491</ArticleId></ArticleIdList></Reference><Reference><Citation>Dabbous HM, Abd-Elsalam S, El-Sayed MH, Sherief AF, Ebeid FFS, Ghafar MSA, et al. . Efficacy of Favipiravir in COVID-19 Treatment: A Multi-Center Randomized Study. Arch Virol (2021) 166(3):949&#x2013;54. doi: 10.1007/s00705-021-04956-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00705-021-04956-9</ArticleId><ArticleId IdType="pmc">PMC7829645</ArticleId><ArticleId IdType="pubmed">33492523</ArticleId></ArticleIdList></Reference><Reference><Citation>
PRINCIPLE . Favipiravir to be Investigated as a Possible COVID-19 Treatment for at-Home Recovery in the PRINCIPLE Trial &#x2014; PRINCIPLE Trial. (2021). (https://www.principletrial.org/news/favipiravir-to-be-investigated-as-a-possible-covid-19-treatment-for-at-home-recovery-in-the-principle-trial [Accessed September 23,2021]</Citation></Reference><Reference><Citation>Painter WP, Holman W, Bush JA, Almazedi F, Malik H, Eraut NCJE, et al. . Human Safety, Tolerability, and Pharmacokinetics of Molnupiravir, a Novel Broad-Spectrum Oral Antiviral Agent With Activity Against SARS-CoV-2. Antimicrobial Agents Chemother (2021) 65(5):e02428&#x2013;20. doi: 10.1128/AAC.02428-20</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/AAC.02428-20</ArticleId><ArticleId IdType="pmc">PMC8092915</ArticleId><ArticleId IdType="pubmed">33649113</ArticleId></ArticleIdList></Reference><Reference><Citation>Abdelnabi R, Foo CS, Kaptein SJF, Zhang X, Langendries L, Vangeel L, et al. . The Combined Treatment of Molnupiravir and Favipiravir Results in a Marked Potentiation of Antiviral Efficacy in a SARS-CoV-2 Hamster Infection Model. bioRxiv (2021). doi: 10.1101/2020.12.10.419242</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2020.12.10.419242</ArticleId><ArticleId IdType="pmc">PMC8461366</ArticleId><ArticleId IdType="pubmed">34571361</ArticleId></ArticleIdList></Reference><Reference><Citation>Uzunova K, Filipova E, Pavlova V, Vekov T. Insights Into Antiviral Mechanisms of Remdesivir, Lopinavir/Ritonavir and Chloroquine/Hydroxychloroquine Affecting the New SARS-CoV-2. Biomed Pharmacother (2020) 131:110668. doi: 10.1016/j.biopha.2020.110668</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.biopha.2020.110668</ArticleId><ArticleId IdType="pmc">PMC7444940</ArticleId><ArticleId IdType="pubmed">32861965</ArticleId></ArticleIdList></Reference><Reference><Citation>Cao B, Wang Y, Wen D, Liu W, Wang J, Fan G, et al. . A Trial of Lopinavir&#x2013;Ritonavir in Adults Hospitalized With Severe Covid-19. New Engl J Med (2020) 382(19):1787&#x2013;99. doi: 10.1056/NEJMc2008043</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMc2008043</ArticleId><ArticleId IdType="pmc">PMC7121492</ArticleId><ArticleId IdType="pubmed">32187464</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Y, Xie Z, Lin W, Cai W, Wen C, Guan Y, et al. . Efficacy and Safety of Lopinavir/Ritonavir or Arbidol in Adult Patients With Mild/Moderate COVID-19: An Exploratory Randomized Controlled. Trial Med (2020) 1(1):105&#x2013;13. doi: 10.1016/j.medj.2020.04.001</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.medj.2020.04.001</ArticleId><ArticleId IdType="pmc">PMC7235585</ArticleId><ArticleId IdType="pubmed">32838353</ArticleId></ArticleIdList></Reference><Reference><Citation>Sheahan TP, Sims AC, Leist SR, Sch&#xe4;fer A, Won J, Brown AJ, et al. . Comparative Therapeutic Efficacy of Remdesivir and Combination Lopinavir, Ritonavir, and Interferon Beta Against MERS-CoV. Nat Commun (2020) 11(1):222. doi: 10.1038/s41467-019-13940-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-019-13940-6</ArticleId><ArticleId IdType="pmc">PMC6954302</ArticleId><ArticleId IdType="pubmed">31924756</ArticleId></ArticleIdList></Reference><Reference><Citation>Hung IFN, Lung KC, Tso EYK, Liu R, Chung TWH, Chu MY, et al. . Triple Combination of Interferon Beta-1b, Lopinavir&#x2013;Ritonavir, and Ribavirin in the Treatment of Patients Admitted to Hospital With COVID-19: An Open-Label, Randomised, Phase 2 Trial. Lancet (2020) 395(10238):1695&#x2013;704. doi: 10.1016/S0140-6736(20)31042-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(20)31042-4</ArticleId><ArticleId IdType="pmc">PMC7211500</ArticleId><ArticleId IdType="pubmed">32401715</ArticleId></ArticleIdList></Reference><Reference><Citation>Srinivas P, Sacha GL, Koval C. Antivirals for COVID-19. Cleveland Clin J Med (2020). doi: 10.3949/ccjm.87a.ccc030</Citation><ArticleIdList><ArticleId IdType="doi">10.3949/ccjm.87a.ccc030</ArticleId><ArticleId IdType="pubmed">32409433</ArticleId></ArticleIdList></Reference><Reference><Citation>Cvetkovic RS, Goa KL. Lopinavir/ritonavir: A Review of Its Use in the Management of HIV Infection. Drugs (2003) 63:769&#x2013;802. doi: 10.2165/00003495-200363080-00004</Citation><ArticleIdList><ArticleId IdType="doi">10.2165/00003495-200363080-00004</ArticleId><ArticleId IdType="pubmed">12662125</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang X, Guan Y. COVID-19 Drug Repurposing: A Review of Computational Screening Methods, Clinical Trials, and Protein Interaction Assays. Med Res Rev (2021) 41:5&#x2013;28. doi: 10.1002/med.21728</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/med.21728</ArticleId><ArticleId IdType="pmc">PMC8049524</ArticleId><ArticleId IdType="pubmed">32864815</ArticleId></ArticleIdList></Reference><Reference><Citation>Savarino A, Boelaert JR, Cassone A, Majori G, Cauda R. Effects of Chloroquine on Viral Infections: An Old Drug Against Today&#x2019;s Diseases? Lancet Infect Dis (2003) 3:722&#x2013;7. doi: 10.1016/S1473-3099(03)00806-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(03)00806-5</ArticleId><ArticleId IdType="pmc">PMC7128816</ArticleId><ArticleId IdType="pubmed">14592603</ArticleId></ArticleIdList></Reference><Reference><Citation>Gomes CP, Fernandes DE, Casimiro F, da Mata GF, Passos MT, Varela P, et al. . Cathepsin L in COVID-19: From Pharmacological Evidences to Genetics. Front Cell Infect Microbiol (2020) 10. doi: 10.3389/fcimb.2020.589505</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fcimb.2020.589505</ArticleId><ArticleId IdType="pmc">PMC7753008</ArticleId><ArticleId IdType="pubmed">33364201</ArticleId></ArticleIdList></Reference><Reference><Citation>Ou T, Mou H, Zhang L, Ojha A, Choe H, Farzan M. Hydroxychloroquine-Mediated Inhibition of SARS-CoV-2 Entry is Attenuated by TMPRSS2. PloS Pathogens (2021) 17(1 January):e1009212. doi: 10.1371/journal.ppat.1009212</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.ppat.1009212</ArticleId><ArticleId IdType="pmc">PMC7845965</ArticleId><ArticleId IdType="pubmed">33465165</ArticleId></ArticleIdList></Reference><Reference><Citation>Vincent MJ, Bergeron E, Benjannet S, Erickson BR, Rollin PE, Ksiazek TG, et al. . Chloroquine is a Potent Inhibitor of SARS Coronavirus Infection and Spread. Virol J (2005) 2:69. doi: 10.1186/1743-422X-2-69</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1743-422X-2-69</ArticleId><ArticleId IdType="pmc">PMC1232869</ArticleId><ArticleId IdType="pubmed">16115318</ArticleId></ArticleIdList></Reference><Reference><Citation>Yao X, Ye F, Zhang M, Cui C, Huang B, Niu P, et al. . In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). Clin Infect Dis (2020) 71(15):732&#x2013;9. doi: 10.1093/cid/ciaa237</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciaa237</ArticleId><ArticleId IdType="pmc">PMC7108130</ArticleId><ArticleId IdType="pubmed">32150618</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu J, Cao R, Xu M, Wang X, Zhang H, Hu H, et al. . Hydroxychloroquine, a Less Toxic Derivative of Chloroquine, is Effective in Inhibiting SARS-CoV-2 Infection In Vitro . Cell Discov (2020) 6:16. doi: 10.1038/s41421-020-0156-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41421-020-0156-0</ArticleId><ArticleId IdType="pmc">PMC7078228</ArticleId><ArticleId IdType="pubmed">32194981</ArticleId></ArticleIdList></Reference><Reference><Citation>Keyaerts E, Li S, Vijgen L, Rysman E, Verbeeck J, van Ranst M, et al. . Antiviral Activity of Chloroquine Against Human Coronavirus OC43 Infection in Newborn Mice. Antimicrobial Agents Chemother (2009) 53(8):3416&#x2013;21. doi: 10.1128/AAC.01509-08</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/AAC.01509-08</ArticleId><ArticleId IdType="pmc">PMC2715625</ArticleId><ArticleId IdType="pubmed">19506054</ArticleId></ArticleIdList></Reference><Reference><Citation>Mitj&#xe0; O, Corbacho-Monn&#xe9; M, Ubals M, Alemany A, Su&#xf1;er C, Teb&#xe9; C, et al. . A Cluster-Randomized Trial of Hydroxychloroquine for Prevention of Covid-19. New Engl J Med (2021) 384(5):417&#x2013;27. doi: 10.1056/NEJMoa2021801</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2021801</ArticleId><ArticleId IdType="pmc">PMC7722693</ArticleId><ArticleId IdType="pubmed">33289973</ArticleId></ArticleIdList></Reference><Reference><Citation>Self WH, Semler MW, Leither LM, Casey JD, Angus DC, Brower RG, et al. . Effect of Hydroxychloroquine on Clinical Status at 14 Days in Hospitalized Patients With COVID-19: A Randomized Clinical Trial. JAMA - J Am Med Assoc (2020) 324(21):2165&#x2013;76. doi: 10.1001/jama.2020.22240</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2020.22240</ArticleId><ArticleId IdType="pmc">PMC7653542</ArticleId><ArticleId IdType="pubmed">33165621</ArticleId></ArticleIdList></Reference><Reference><Citation>Geleris J, Sun Y, Platt J, Zucker J, Baldwin M, Hripcsak G, et al. . Observational Study of Hydroxychloroquine in Hospitalized Patients With Covid-19. New Engl J Med (2020) 382(25):2411&#x2013;8. doi: 10.1056/NEJMoa2012410</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2012410</ArticleId><ArticleId IdType="pmc">PMC7224609</ArticleId><ArticleId IdType="pubmed">32379955</ArticleId></ArticleIdList></Reference><Reference><Citation>Thomson K, Nachlis H. Emergency Use Authorizations During the COVID-19 Pandemic: Lessons From Hydroxychloroquine for Vaccine Authorization and Approval. JAMA - J Am Med Assoc (2020) 324:1282&#x2013;3. doi: 10.1001/jama.2020.16253</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2020.16253</ArticleId><ArticleId IdType="pubmed">32870235</ArticleId></ArticleIdList></Reference><Reference><Citation>Hussain M, Jabeen N, Amanullah A, Baig AA, Aziz B, Shabbir S, et al. . Structural Basis of SARS-CoV-2 Spike Protein Priming by TMPRSS2. AIMS Microbiol (2020) 6(3):350&#x2013;60. doi: 10.3934/microbiol.2020021</Citation><ArticleIdList><ArticleId IdType="doi">10.3934/microbiol.2020021</ArticleId><ArticleId IdType="pmc">PMC7535071</ArticleId><ArticleId IdType="pubmed">33029570</ArticleId></ArticleIdList></Reference><Reference><Citation>Benton DJ, Wrobel AG, Xu P, Roustan C, Martin SR, Rosenthal PB, et al. . Receptor Binding and Priming of the Spike Protein of SARS-CoV-2 for Membrane Fusion. Nature (2020) 588(7837):327&#x2013;30. doi: 10.1038/s41586-020-2772-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-020-2772-0</ArticleId><ArticleId IdType="pmc">PMC7116727</ArticleId><ArticleId IdType="pubmed">32942285</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoffmann M, Hofmann-Winkler H, Smith JC, Kr&#xfc;ger N, Arora P, S&#xf8;rensen LK, et al. . Camostat Mesylate Inhibits SARS-CoV-2 Activation by TMPRSS2-Related Proteases and Its Metabolite GBPA Exerts Antiviral Activity. EBioMedicine (2021) 65:103255. doi: 10.1016/j.ebiom.2021.103255</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ebiom.2021.103255</ArticleId><ArticleId IdType="pmc">PMC7930809</ArticleId><ArticleId IdType="pubmed">33676899</ArticleId></ArticleIdList></Reference><Reference><Citation>Kupferschmidt K. These Drugs Don&#x2019;t Target the Coronavirus&#x2014;They Target Us. Science (2020). doi: 10.1126/science.abc0405</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abc0405</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoffmann M, Schroeder S, Kleine-Weber H, M&#xfc;ller MA, Drosten C, P&#xf6;hlmann S. Nafamostat Mesylate Blocks Activation of SARS-CoV-2: New Treatment Option for COVID-19. Antimicrobial Agents Chemother (2020) 64(6):e00754&#x2013;20. doi: 10.1128/AAC.00754-20</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/AAC.00754-20</ArticleId><ArticleId IdType="pmc">PMC7269515</ArticleId><ArticleId IdType="pubmed">32312781</ArticleId></ArticleIdList></Reference><Reference><Citation>Breining P, Fr&#xf8;lund AL, H&#xf8;jen JF, Gunst JD, Staerke NB, Saedder E, et al. . Camostat Mesylate Against SARS-CoV-2 and COVID-19&#x2014;Rationale, Dosing and Safety. Basic Clin Pharmacol Toxicol (2021) 128(2):204&#x2013;12. doi: 10.1111/bcpt.13533</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/bcpt.13533</ArticleId><ArticleId IdType="pubmed">33176395</ArticleId></ArticleIdList></Reference><Reference><Citation>Luan B, Huynh T, Cheng X, Lan G, Wang HR. Targeting Proteases for Treating COVID-19. J Proteome Res (2020) 19:4316&#x2013;26. doi: 10.1021/acs.jproteome.0c00430</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acs.jproteome.0c00430</ArticleId><ArticleId IdType="pubmed">33090793</ArticleId></ArticleIdList></Reference><Reference><Citation>Seth S, Batra J, Srinivasan S. COVID-19: Targeting Proteases in Viral Invasion and Host Immune Response. Front Mol Biosci (2020) 7. doi: 10.3389/fmolb.2020.00215</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmolb.2020.00215</ArticleId><ArticleId IdType="pmc">PMC7581869</ArticleId><ArticleId IdType="pubmed">33195400</ArticleId></ArticleIdList></Reference><Reference><Citation>Schloer S, Brunotte L, Goretzko J, Mecate-Zambrano A, Korthals N, Gerke V, et al. . Targeting the Endolysosomal Host-SARS-CoV-2 Interface by Clinically Licensed Functional Inhibitors of Acid Sphingomyelinase (FIASMA) Including the Antidepressant Fluoxetine. Emerging Microbes Infect (2020) 9(1):2245&#x2013;55. doi: 10.1080/22221751.2020.1829082</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/22221751.2020.1829082</ArticleId><ArticleId IdType="pmc">PMC7594754</ArticleId><ArticleId IdType="pubmed">32975484</ArticleId></ArticleIdList></Reference><Reference><Citation>Zimniak M, Kirschner L, Hilpert H, Geiger N, Danov O, Oberwinkler H, et al. . The Serotonin Reuptake Inhibitor Fluoxetine Inhibits SARS-CoV-2 in Human Lung Tissue. Sci Rep (2021) 11(1):5890. doi: 10.1038/s41598-021-85049-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-021-85049-0</ArticleId><ArticleId IdType="pmc">PMC7961020</ArticleId><ArticleId IdType="pubmed">33723270</ArticleId></ArticleIdList></Reference><Reference><Citation>Schloer S, Brunotte L, Mecate-Zambrano A, Zheng S, Tang J, Ludwig S, et al. . Drug Synergy of Combinatory Treatment With Remdesivir and the Repurposed Drugs Fluoxetine and Itraconazole Effectively Impairs SARS-CoV-2 Infection In Vitro . Br J Pharmacol (2021) 178(11):2339&#x2013;50. doi: 10.1111/bph.15418</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/bph.15418</ArticleId><ArticleId IdType="pmc">PMC8251190</ArticleId><ArticleId IdType="pubmed">33825201</ArticleId></ArticleIdList></Reference><Reference><Citation>Creeden JF, Imami AS, Eby HM, Gillman C, Becker KN, Reigle J, et al. . Fluoxetine as an Anti-Inflammatory Therapy in SARS-CoV-2 Infection. Biomed Pharmacother (2021) 138:111437. doi: 10.1016/j.biopha.2021.111437</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.biopha.2021.111437</ArticleId><ArticleId IdType="pmc">PMC7904450</ArticleId><ArticleId IdType="pubmed">33691249</ArticleId></ArticleIdList></Reference><Reference><Citation>Eugene AR. Fluoxetine Pharmacokinetics and Tissue Distribution Suggest a Possible Role in Reducing SARS-CoV-2 Titers [version 1; peer review: 2 approved with reservations]. F1000Research (2021) 10:477. doi: 10.12688/f1000research.53275.1</Citation><ArticleIdList><ArticleId IdType="doi">10.12688/f1000research.53275.1</ArticleId><ArticleId IdType="pmc">PMC9561539</ArticleId><ArticleId IdType="pubmed">36262792</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoertel N, S&#xe1;nchez-Rico M, Vernet R, Beeker N, Jannot AS, Neuraz A, et al. . Association Between Antidepressant Use and Reduced Risk of Intubation or Death in Hospitalized Patients With COVID-19: Results From an Observational Study. Mol Psychiatry (2021). doi: 10.1038/s41380-021-01021-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41380-021-01021-4</ArticleId><ArticleId IdType="pubmed">33536545</ArticleId></ArticleIdList></Reference><Reference><Citation>Gordon DE, Jang GM, Bouhaddou M, Xu J, Obernier K, White KM, et al. . A SARS-CoV-2 Protein Interaction Map Reveals Targets for Drug Repurposing. Nature (2020) 583(7816):459&#x2013;68. doi: 10.1038/s41586-020-2286-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-020-2286-9</ArticleId><ArticleId IdType="pmc">PMC7431030</ArticleId><ArticleId IdType="pubmed">32353859</ArticleId></ArticleIdList></Reference><Reference><Citation>Delgado-Calle J, Kurihara N, Atkinson EG, Nelson J, Miyagawa K, Galmarini CM, et al. . Aplidin (Plitidepsin) is a Novel Anti-Myeloma Agent With Potent Anti-Resorptive Activity Mediated by Direct Effects on Osteoclasts. Oncotarget (2019) 10(28):2709&#x2013;21. doi: 10.18632/oncotarget.26831</Citation><ArticleIdList><ArticleId IdType="doi">10.18632/oncotarget.26831</ArticleId><ArticleId IdType="pmc">PMC6505631</ArticleId><ArticleId IdType="pubmed">31105871</ArticleId></ArticleIdList></Reference><Reference><Citation>Wong JP, Damania B. SARS-CoV-2 Dependence on Host Pathways. Science (2021) 371:884&#x2013;5. doi: 10.1126/science.abg6837</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abg6837</ArticleId><ArticleId IdType="pubmed">33632832</ArticleId></ArticleIdList></Reference><Reference><Citation>White KM, Rosales R, Yildiz S, Kehrer T, Miorin L, Moreno E, et al. . Plitidepsin has Potent Preclinical Efficacy Against SARS-CoV-2 by Targeting the Host Protein Eef1a. Science (2021) 371(6532):926&#x2013;31. doi: 10.1126/science.abf4058</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abf4058</ArticleId><ArticleId IdType="pmc">PMC7963220</ArticleId><ArticleId IdType="pubmed">33495306</ArticleId></ArticleIdList></Reference><Reference><Citation>Reuschl A-K, Thorne L, Zuliani Alvarez L, Bouhaddou M, Obernier K, Soucheray M, et al. . Host-Directed Therapies Against Early-Lineage SARS-CoV-2 Retain Efficacy Against B.1.1.7 Variant. bioRxiv: Preprint Server Biol (2021). doi: 10.1101/2021.01.24.427991</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2021.01.24.427991</ArticleId></ArticleIdList></Reference><Reference><Citation>Spicka I, Ocio EM, Oakervee HE, Greil R, Banh RH, Huang SY, et al. . Randomized Phase III Study (ADMYRE) of Plitidepsin in Combination With Dexamethasone vs. Dexamethasone Alone in Patients With Relapsed/Refractory Multiple Myeloma. Ann Hematol (2019) 98(9):2139&#x2013;50. doi: 10.1007/s00277-019-03739-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00277-019-03739-2</ArticleId><ArticleId IdType="pmc">PMC6700046</ArticleId><ArticleId IdType="pubmed">31240472</ArticleId></ArticleIdList></Reference><Reference><Citation>Planz O. Development of Cellular Signaling Pathway Inhibitors as New Antivirals Against Influenza. Antiviral Res (2013) 98:457&#x2013;68. doi: 10.1016/j.antiviral.2013.04.008</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.antiviral.2013.04.008</ArticleId><ArticleId IdType="pubmed">23603495</ArticleId></ArticleIdList></Reference><Reference><Citation>Pleschka S, Wolff T, Ehrhardt C, Hobom G, Planz O, Rapp UR, et al. . Influenza Virus Propagation is Impaired by Inhibition of the Raf/MEK/ERK Signalling Cascade. Nat Cell Biol (2001) 3(3):301&#x2013;5. doi: 10.1038/35060098</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/35060098</ArticleId><ArticleId IdType="pubmed">11231581</ArticleId></ArticleIdList></Reference><Reference><Citation>Schreiber A, Boff L, Anhlan D, Krischuns T, Brunotte L, Schuberth C, et al. . Dissecting the Mechanism of Signaling-Triggered Nuclear Export of Newly Synthesized Influenza Virus Ribonucleoprotein Complexes. Proc Natl Acad Sci USA (2020) 117(28):16557&#x2013;66. doi: 10.1073/pnas.2002828117</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.2002828117</ArticleId><ArticleId IdType="pmc">PMC7368312</ArticleId><ArticleId IdType="pubmed">32601201</ArticleId></ArticleIdList></Reference><Reference><Citation>Preugschas HF, Hrincius ER, Mewis C, Tran GVQ, Ludwig S, Ehrhardt C. Late Activation of the Raf/MEK/ERK Pathway is Required for Translocation of the Respiratory Syncytial Virus F Protein to the Plasma Membrane and Efficient Viral Replication. Cell Microbiol (2019) 21(1):e12955. doi: 10.1111/cmi.12955</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/cmi.12955</ArticleId><ArticleId IdType="pubmed">30223301</ArticleId></ArticleIdList></Reference><Reference><Citation>Cai Y, Liu Y, Zhang X. Suppression of Coronavirus Replication by Inhibition of the MEK Signaling Pathway. J Virol (2007) 81(2):446&#x2013;56. doi: 10.1128/JVI.01705-06</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.01705-06</ArticleId><ArticleId IdType="pmc">PMC1797436</ArticleId><ArticleId IdType="pubmed">17079328</ArticleId></ArticleIdList></Reference><Reference><Citation>Laure M, Hamza H, Koch-Heier J, Quernheim M, M&#xfc;ller C, Schreiber A, et al. . Antiviral Efficacy Against Influenza Virus and Pharmacokinetic Analysis of a Novel MEK-Inhibitor, ATR-002, in Cell Culture and in the Mouse Model. Antiviral Res (2020) 178:104806. doi: 10.1016/j.antiviral.2020.104806</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.antiviral.2020.104806</ArticleId><ArticleId IdType="pubmed">32304723</ArticleId></ArticleIdList></Reference><Reference><Citation>Pinto R, Herold S, Cakarova L, Hoegner K, Lohmeyer J, Planz O, et al. . Inhibition of Influenza Virus-Induced NF-kappaB and Raf/MEK/ERK Activation can Reduce Both Virus Titers and Cytokine Expression Simultaneously In Vitro and In Vivo . Antiviral Res (2011) 92(1):45&#x2013;56. doi: 10.1016/j.antiviral.2011.05.009</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.antiviral.2011.05.009</ArticleId><ArticleId IdType="pubmed">21641936</ArticleId></ArticleIdList></Reference><Reference><Citation>Zaidi AK, Dehgani-Mobaraki P. The Mechanisms of Action of Ivermectin Against SARS-CoV-2: An Evidence-Based Clinical Review Article. J&#xa0;Antibiotics (2021). doi: 10.1038/s41429-021-00430-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41429-021-00430-5</ArticleId><ArticleId IdType="pmc">PMC8203399</ArticleId><ArticleId IdType="pubmed">34127807</ArticleId></ArticleIdList></Reference><Reference><Citation>Matsuyama T, Kubli SP, Yoshinaga SK, Pfeffer K, Mak TW. An Aberrant STAT Pathway is Central to COVID-19. Cell Death Different (2020) 27:3209&#x2013;25. doi: 10.1038/s41418-020-00633-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41418-020-00633-7</ArticleId><ArticleId IdType="pmc">PMC7545020</ArticleId><ArticleId IdType="pubmed">33037393</ArticleId></ArticleIdList></Reference><Reference><Citation>Caly L, Druce JD, Catton MG, Jans DA, Wagstaff KM. The FDA-Approved Drug Ivermectin Inhibits the Replication of SARS-CoV-2 In Vitro . Antiviral Res (2020) 178:104787. doi: 10.1016/j.antiviral.2020.104787</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.antiviral.2020.104787</ArticleId><ArticleId IdType="pmc">PMC7129059</ArticleId><ArticleId IdType="pubmed">32251768</ArticleId></ArticleIdList></Reference><Reference><Citation>Kory P, Meduri GU, Varon J, Iglesias J, Marik PE. Review of the Emerging Evidence Demonstrating the Efficacy of Ivermectin in the Prophylaxis and Treatment of COVID-19. Am J Ther (2021) 28(3):e299&#x2013;318. doi: 10.1097/MJT.0000000000001377</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MJT.0000000000001377</ArticleId><ArticleId IdType="pmc">PMC8088823</ArticleId><ArticleId IdType="pubmed">34375047</ArticleId></ArticleIdList></Reference><Reference><Citation>Camprub&#xed; D, Almuedo-Riera A, Mart&#xed;-Soler HI, Soriano A, Hurtado JC, Subir&#xe0; C, et al. . Lack of Efficacy of Standard Doses of Ivermectin in Severe COVID-19 Patients. PloS One (2020) 15(11):e0242184. doi: 10.1371/journal.pone.0242184</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0242184</ArticleId><ArticleId IdType="pmc">PMC7657540</ArticleId><ArticleId IdType="pubmed">33175880</ArticleId></ArticleIdList></Reference><Reference><Citation>Chaccour C, Hammann F, Ram&#xf3;n-Garc&#xed;a S, Rabinovich NR. Ivermectin and COVID-19: Keeping Rigor in Times of Urgency. Am J Trop Med Hygiene (2020) 102:1156&#x2013;7. doi: 10.4269/ajtmh.20-0271</Citation><ArticleIdList><ArticleId IdType="doi">10.4269/ajtmh.20-0271</ArticleId><ArticleId IdType="pmc">PMC7253113</ArticleId><ArticleId IdType="pubmed">32314704</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang R, Simoneau CR, Kulsuptrakul J, Bouhaddou M, Travisano KA, Hayashi JM, et al. . Genetic Screens Identify Host Factors for SARS-CoV-2 and Common Cold Coronaviruses. Cell (2021) 184(1):106&#x2013;19. doi: 10.1016/j.cell.2020.12.004</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2020.12.004</ArticleId><ArticleId IdType="pmc">PMC7723770</ArticleId><ArticleId IdType="pubmed">33333024</ArticleId></ArticleIdList></Reference><Reference><Citation>Daniloski Z, Jordan TX, Wessels HH, Hoagland DA, Kasela S, Legut M, et al. . Identification of Required Host Factors for SARS-CoV-2 Infection in Human Cells. Cell (2021) 184(1):92&#x2013;105. doi: 10.1016/j.cell.2020.10.030</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2020.10.030</ArticleId><ArticleId IdType="pmc">PMC7584921</ArticleId><ArticleId IdType="pubmed">33147445</ArticleId></ArticleIdList></Reference><Reference><Citation>mac Kain A, Maarifi G, Aicher S-M, Arhel N, Baidaliuk A, Vallet T, et al. . Identification of DAXX As A Restriction Factor Of SARS-CoV-2 Through A CRISPR/Cas9 Screen. bioRxiv (2021) 58(12). doi: 10.1101/2021.05.06.442916</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2021.05.06.442916</ArticleId><ArticleId IdType="pmc">PMC9068693</ArticleId><ArticleId IdType="pubmed">35508460</ArticleId></ArticleIdList></Reference><Reference><Citation>Biering SB, Sarnik SA, Wang E, Zengel JR, Sathyan V, Nguyenla X, et al. . Genome-Wide, Bidirectional CRISPR Screens Identify Mucins as Critical Host Factors Modulating SARS-CoV-2 Infection. bioRxiv (2021). doi: 10.1101/2021.04.22.440848</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2021.04.22.440848</ArticleId><ArticleId IdType="pmc">PMC9355872</ArticleId><ArticleId IdType="pubmed">35879412</ArticleId></ArticleIdList></Reference><Reference><Citation>Baggen J, Persoons L, Vanstreels E, Jansen S, van Looveren D, Boeckx B, et al. . Genome-Wide CRISPR Screening Identifies TMEM106B as a Proviral Host Factor for SARS-CoV-2. Nat Genet (2021) 53(4):435&#x2013;44. doi: 10.1038/s41588-021-00805-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41588-021-00805-2</ArticleId><ArticleId IdType="pubmed">33686287</ArticleId></ArticleIdList></Reference><Reference><Citation>Lazear HM, Schoggins JW, Diamond MS. Shared and Distinct Functions of Type I and Type III Interferons. Immunity (2019) 50:907&#x2013;23. doi: 10.1016/j.immuni.2019.03.025</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.immuni.2019.03.025</ArticleId><ArticleId IdType="pmc">PMC6839410</ArticleId><ArticleId IdType="pubmed">30995506</ArticleId></ArticleIdList></Reference><Reference><Citation>Gibbert K, Schlaak JF, Yang D, Dittmer U. IFN-&#x3b1; Subtypes: Distinct Biological Activities in Anti-Viral Therapy. Br J Pharmacol (2013) 168:1048&#x2013;58. doi: 10.1111/bph.12010</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/bph.12010</ArticleId><ArticleId IdType="pmc">PMC3594665</ArticleId><ArticleId IdType="pubmed">23072338</ArticleId></ArticleIdList></Reference><Reference><Citation>Lokugamage KG, Hage A, de Vries M, Valero-Jimenez AM, Schindewolf C, Dittmann D, et al. . Type I Interferon Susceptibility Distinguishes SARS-CoV-2 from SARS-CoV. J Virol (2020) 94(23):e01410&#x2013;20. doi: 10.1128/JVI.01410-20</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.01410-20</ArticleId><ArticleId IdType="pmc">PMC7654262</ArticleId><ArticleId IdType="pubmed">32938761</ArticleId></ArticleIdList></Reference><Reference><Citation>Mantlo E, Bukreyeva N, Maruyama J, Paessler S, Huang C. Antiviral Activities of Type I Interferons to SARS-CoV-2 Infection. Antiviral Res (2020) 179:104811. doi: 10.1016/j.antiviral.2020.104811</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.antiviral.2020.104811</ArticleId><ArticleId IdType="pmc">PMC7188648</ArticleId><ArticleId IdType="pubmed">32360182</ArticleId></ArticleIdList></Reference><Reference><Citation>Baghaei P, Dastan F, Marjani M, Moniri A, Abtahian Z, Ghadimi S, et al. . Combination Therapy of Ifn&#x3b2;1 With Lopinavir&#x2013;Ritonavir, Increases Oxygenation, Survival and Discharging of Sever COVID-19 Infected Inpatients. Int Immunopharmacol (2021) 92:107329. doi: 10.1016/j.intimp.2020.107329</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.intimp.2020.107329</ArticleId><ArticleId IdType="pmc">PMC7762801</ArticleId><ArticleId IdType="pubmed">33412395</ArticleId></ArticleIdList></Reference><Reference><Citation>Rahmani H, Davoudi-Monfared E, Nourian A, Khalili H, Hajizadeh N, Jalalabadi NZ, et al. . Interferon &#x3b2;-1b in Treatment of Severe COVID-19: A Randomized Clinical Trial. Int Immunopharmacol (2020) 88:106903. doi: 10.1016/j.intimp.2020.106903</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.intimp.2020.106903</ArticleId><ArticleId IdType="pmc">PMC7445008</ArticleId><ArticleId IdType="pubmed">32862111</ArticleId></ArticleIdList></Reference><Reference><Citation>Davoudi-Monfared E, Rahmani H, Khalili H, Hajiabdolbaghi M, Salehi M, Abbasian L, et al. . A Randomized Clinical Trial of the Efficacy and Safety of Interferon &#x3b2;-1a in Treatment of Severe COVID-19. Antimicrobial Agents Chemother (2020) 64(9):e01061&#x2013;20. doi: 10.1128/AAC.01061-20</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/AAC.01061-20</ArticleId><ArticleId IdType="pmc">PMC7449227</ArticleId><ArticleId IdType="pubmed">32661006</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou Q, Chen V, Shannon CP, Wei XS, Xiang X, Wang X, et al. . Interferon-&#x3b1;2b Treatment for COVID-19. Front Immunol (2020) 11. doi: 10.3389/fimmu.2020.01061</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2020.01061</ArticleId><ArticleId IdType="pmc">PMC7242746</ArticleId><ArticleId IdType="pubmed">32574262</ArticleId></ArticleIdList></Reference><Reference><Citation>Monk PD, Marsden RJ, Tear VJ, Brookes J, Batten TN, Mankowski M, et al. . Safety and Efficacy of Inhaled Nebulised Interferon Beta-1a (SNG001) for Treatment of SARS-CoV-2 Infection: A Randomised, Double-Blind, Placebo-Controlled, Phase 2 Trial. Lancet Respir Med (2021) 9(2):196&#x2013;206. doi: 10.1016/S2213-2600(20)30511-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2213-2600(20)30511-7</ArticleId><ArticleId IdType="pmc">PMC7836724</ArticleId><ArticleId IdType="pubmed">33189161</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang N, Zhan Y, Zhu L, Hou Z, Liu F, Song P, et al. . Retrospective Multicenter Cohort Study Shows Early Interferon Therapy Is Associated With Favorable Clinical Responses in COVID-19 Patients. Cell Host Microbe (2020) 28(3):455&#x2013;64. doi: 10.1016/j.chom.2020.07.005</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.chom.2020.07.005</ArticleId><ArticleId IdType="pmc">PMC7368656</ArticleId><ArticleId IdType="pubmed">32707096</ArticleId></ArticleIdList></Reference><Reference><Citation>Est&#xe9;banez M, Ram&#xed;rez-Olivencia G, Mata T, Mart&#xed; D, Gutierrez C, de Dios B, et al. . Clinical Evaluation of IFN Beta1b in COVID-19 Pneumonia: A Retrospective Study. bioRxiv (2020). doi: 10.1101/2020.05.15.20084293</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2020.05.15.20084293</ArticleId></ArticleIdList></Reference><Reference><Citation>Schuhenn J, Meister TL, Todt D, Bracht T, Schork K, Billaud J-N, et al. . Differential Interferon-&#x3b1; Subtype Immune Signatures Suppress SARS-CoV-2 Infection. bioRxiv (2021). doi: 10.1101/2021.05.20.444757</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2021.05.20.444757</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo K, Barrett BS, Mickens KL, Hasenkrug KJ, Santiago M. Interferon Resistance of Emerging SARS-CoV-2 Variants. bioRxiv (2021). doi: 10.1101/2021.03.20.436257</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2021.03.20.436257</ArticleId><ArticleId IdType="pmc">PMC9371743</ArticleId><ArticleId IdType="pubmed">35867811</ArticleId></ArticleIdList></Reference><Reference><Citation>Vanderheiden A, Ralfs P, Chirkova T, Upadhyay AA, Zimmerman MG, Bedoya S, et al. . Type I and Type III Interferons Restrict SARS-CoV-2 Infection of Human Airway Epithelial Cultures. J Virol (2020) 94(19):e00985&#x2013;20. doi: 10.1128/JVI.00985-20</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.00985-20</ArticleId><ArticleId IdType="pmc">PMC7495371</ArticleId><ArticleId IdType="pubmed">32699094</ArticleId></ArticleIdList></Reference><Reference><Citation>Dinnon KH, Leist SR, Sch&#xe4;fer A, Edwards CE, Martinez DR, Montgomery SA, et al. . A Mouse-Adapted Model of SARS-CoV-2 to Test COVID-19 Countermeasures. Nature (2020) 586(7830):560&#x2013;6. doi: 10.1038/s41586-020-2708-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-020-2708-8</ArticleId><ArticleId IdType="pmc">PMC8034761</ArticleId><ArticleId IdType="pubmed">32854108</ArticleId></ArticleIdList></Reference><Reference><Citation>Jagannathan P, Andrews JR, Bonilla H, Hedlin H, Jacobson KB, Balasubramanian V, et al. . Peginterferon Lambda-1a for Treatment of Outpatients With Uncomplicated COVID-19: A Randomized Placebo-Controlled Trial. Nat Commun (2021) 12(1):1967. doi: 10.21203/rs.3.rs-110659/v1</Citation><ArticleIdList><ArticleId IdType="doi">10.21203/rs.3.rs-110659/v1</ArticleId><ArticleId IdType="pmc">PMC8009873</ArticleId><ArticleId IdType="pubmed">33785743</ArticleId></ArticleIdList></Reference><Reference><Citation>Feld JJ, Kandel C, Biondi MJ, Kozak RA, Zahoor MA, Lemieux C, et al. . Peginterferon Lambda for the Treatment of Outpatients With COVID-19: A Phase 2, Placebo-Controlled Randomised Trial. Lancet Respir Med (2021) 9(5):498&#x2013;510. doi: 10.1016/S2213-2600(20)30566-X</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2213-2600(20)30566-X</ArticleId><ArticleId IdType="pmc">PMC7906707</ArticleId><ArticleId IdType="pubmed">33556319</ArticleId></ArticleIdList></Reference><Reference><Citation>Braga Emidio N, Hoffmann W, Brierley SM, Muttenthaler M. Trefoil Factor Family: Unresolved Questions and Clinical Perspectives. Trends Biochem Sci (2019) 44:387&#x2013;90. doi: 10.1016/j.tibs.2019.01.004</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tibs.2019.01.004</ArticleId><ArticleId IdType="pmc">PMC6557713</ArticleId><ArticleId IdType="pubmed">30792027</ArticleId></ArticleIdList></Reference><Reference><Citation>Fu W, Liu Y, Liu L, Hu H, Cheng X, Liu P, et al. . An Open-Label, Randomized Trial of the Combination of IFN-&#x3ba; Plus TFF2 With Standard Care in the Treatment of Patients With Moderate COVID-19. EClinicalMedicine (2020) 27:100547. doi: 10.1016/j.eclinm.2020.100547</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.eclinm.2020.100547</ArticleId><ArticleId IdType="pmc">PMC7502282</ArticleId><ArticleId IdType="pubmed">32984784</ArticleId></ArticleIdList></Reference><Reference><Citation>Li C, Luo F, Liu C, Xiong N, Xu Z, Zhang W, et al. . Effect of a Genetically Engineered Interferon-Alpha Versus Traditional Interferon-Alpha in the Treatment of Moderate-to-Severe COVID-19: A Randomised Clinical Trial. Ann Med (2021) 53(1):391&#x2013;401. doi: 10.1080/07853890.2021.1890329</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/07853890.2021.1890329</ArticleId><ArticleId IdType="pmc">PMC7906612</ArticleId><ArticleId IdType="pubmed">33620016</ArticleId></ArticleIdList></Reference><Reference><Citation>Scagnolari C, Vicenzi E, Bellomi F, Stillitano MG, Pinna D, Poli G, et al. . Increased Sensitivity of SARS-Coronavirus to a Combination of Human Type I and Type II Interferons. Antiviral Ther (2004) 9(6):1003&#x2013;11.</Citation><ArticleIdList><ArticleId IdType="pubmed">15651759</ArticleId></ArticleIdList></Reference><Reference><Citation>Sainz B, Mossel EC, Peters CJ, Garry RF. Interferon-Beta and Interferon-Gamma Synergistically Inhibit the Replication of Severe Acute Respiratory Syndrome-Associated Coronavirus (SARS-CoV). Virology (2004) 329(1):11&#x2013;7. doi: 10.1016/j.virol.2004.08.011</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.virol.2004.08.011</ArticleId><ArticleId IdType="pmc">PMC7111895</ArticleId><ArticleId IdType="pubmed">15476870</ArticleId></ArticleIdList></Reference><Reference><Citation>Mossel EC, Sainz B, Garry RF, Peters CJ. Synergistic Inhibition of SARS-Coronavirus Replication by Type I and Type II IFN. Adv Exp Med Biol (2006) 581:503&#x2013;6. doi: 10.1007/978-0-387-33012-9_89.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/978-0-387-33012-9_89</ArticleId><ArticleId IdType="pmc">PMC7123288</ArticleId><ArticleId IdType="pubmed">17037585</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoshikawa T, Hill TE, Yoshikawa N, Popov VL, Galindo CL, Garner HR, et al. . Dynamic Innate Immune Responses of Human Bronchial Epithelial Cells to Severe Acute Respiratory Syndrome-Associated Coronavirus Infection. PloS One (2010) 5(1):e8729. doi: 10.1371/journal.pone.0008729</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0008729</ArticleId><ArticleId IdType="pmc">PMC2806919</ArticleId><ArticleId IdType="pubmed">20090954</ArticleId></ArticleIdList></Reference><Reference><Citation>Esquivel-Moynelo II, Vazquez-Blonquist DD, Cervantes CL, Campa-Legra II, Vizcaino TM, Lucila Muzio-Gonzalez VV, et al. . Title: Effect of Combination of Interferon Alpha-2b and Interferon-Gamma or Interferon Alpha-2b Alone for Elimination of SARS-CoV-2 Viral RNA. Preliminary Results of a Randomized Controlled Clinical Trial. Available at: https://doi.org/10.1101/2020.07.29.20164251.</Citation></Reference><Reference><Citation>Kumaki Y, Ennis J, Rahbar R, Turner JD, Wandersee MK, Smith AJ, et al. . Single-Dose Intranasal Administration With Mdef201 (Adenovirus Vectored Mouse Interferon-Alpha) Confers Protection From Mortality in a Lethal SARS-CoV BALB/c Mouse Model. Antiviral Res (2011) 89(1):75&#x2013;82. doi: 10.1016/j.antiviral.2010.11.007</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.antiviral.2010.11.007</ArticleId><ArticleId IdType="pmc">PMC3018546</ArticleId><ArticleId IdType="pubmed">21093489</ArticleId></ArticleIdList></Reference><Reference><Citation>Meng Z, Wang T, Chen L, Chen X, Li L, Qin X, et al. . The Effect of Recombinant Human Interferon Alpha Nasal Drops to Prevent COVID-19 Pneumonia for Medical Staff in an Epidemic Area. Curr Top Med Chem (2021) 21(10):920&#x2013;7. doi: 10.2174/1568026621666210429083050</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/1568026621666210429083050</ArticleId><ArticleId IdType="pubmed">33970846</ArticleId></ArticleIdList></Reference><Reference><Citation>Sch&#xe4;cke H, D&#xf6;cke WD, Asadullah K. Mechanisms Involved in the Side Effects of Glucocorticoids. Pharmacol Ther (2002) 96:23&#x2013;43. doi: 10.2174/1568026621666210429083050</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/1568026621666210429083050</ArticleId><ArticleId IdType="pubmed">12441176</ArticleId></ArticleIdList></Reference><Reference><Citation>Poetker DM, Reh DD. A Comprehensive Review of the Adverse Effects of Systemic Corticosteroids. Otolaryngol Clin North Am (2010) 43:753&#x2013;68. doi: 10.1016/j.otc.2010.04.003</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.otc.2010.04.003</ArticleId><ArticleId IdType="pubmed">20599080</ArticleId></ArticleIdList></Reference><Reference><Citation>Ledford H. Coronavirus Breakthrough: Dexamethasone is First Drug Shown to Save Lives. Nature (2020) 582:469. doi: 10.1038/d41586-020-01824-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/d41586-020-01824-5</ArticleId><ArticleId IdType="pubmed">32546811</ArticleId></ArticleIdList></Reference><Reference><Citation>Bertram K, Susan M, Chrousos G.Chapter 39: Adrenocorticosteroids &amp; Adrenocortical Antagonists. Basic and Clinical Pharmacology: Edition 12 (Access Medicine). Edited by Katzung BG, Kruidering-Hall M, Trevor AJ. (2012).</Citation></Reference><Reference><Citation>Segal BH, Sneller MC. Infectious Complications of Immunosuppressive Therapy in Patients With Rheumatic Diseases. Rheumatic Dis Clinics North Am (1997) 23(2):219&#x2013;23. doi: 10.1016/S0889-857X(05)70327-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0889-857X(05)70327-6</ArticleId><ArticleId IdType="pubmed">9156390</ArticleId></ArticleIdList></Reference><Reference><Citation>RECOVERY Collaborative Group. Horby P, Lim WS, Emberson J, Mafham M, Bell J, et al. . Dexamethasone in Hospitalized Patients with Covid-19. N Engl J Med (2020) 384(8):693&#x2013;704. doi: 10.1056/NEJMoa2021436</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2021436</ArticleId><ArticleId IdType="pmc">PMC7383595</ArticleId><ArticleId IdType="pubmed">32678530</ArticleId></ArticleIdList></Reference><Reference><Citation>Villar J, Ferrando C, Mart&#xed;nez D, Ambr&#xf3;s A, Mu&#xf1;oz T, Soler JA, et al. . Dexamethasone Treatment for the Acute Respiratory Distress Syndrome: A Multicentre, Randomised Controlled Trial. Lancet Respir Med (2020) 8(3):267&#x2013;76. doi: 10.1016/S2213-2600(19)30417-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2213-2600(19)30417-5</ArticleId><ArticleId IdType="pubmed">32043986</ArticleId></ArticleIdList></Reference><Reference><Citation>Tomazini BM, Maia IS, Cavalcanti AB, Berwanger O, Rosa RG, Veiga VC, et al. . Effect of Dexamethasone on Days Alive and Ventilator-Free in Patients With Moderate or Severe Acute Respiratory Distress Syndrome and COVID-19: The CoDEX Randomized Clinical Trial. JAMA - J Am Med Assoc (2020) 324(13):1307&#x2013;16. doi: 10.1001/jama.2020.17021</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2020.17021</ArticleId><ArticleId IdType="pmc">PMC7489411</ArticleId><ArticleId IdType="pubmed">32876695</ArticleId></ArticleIdList></Reference><Reference><Citation>Garibaldi BT, Wang K, Robinson ML, Zeger SL, Roche KB, Wang M-C, et al. . Effectiveness of Remdesivir With and Without Dexamethasone in Hospitalized Patients With COVID-19. medRxiv (2020). doi: 10.1101/2020.11.19.20234153</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2020.11.19.20234153</ArticleId></ArticleIdList></Reference><Reference><Citation>Herold T, Jurinovic V, Arnreich C, Hellmuth J, von Bergwelt-Baildon M, Klein M, et al. . Level of IL-6 Predicts Respiratory Failure in Hospitalized Symptomatic COVID-19 Patients. J Allergy Clin Immunol (2020) 146(1):128&#x2013;36.e4. doi: 10.1016/j.jaci.2020.05.008</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jaci.2020.05.008</ArticleId><ArticleId IdType="pmc">PMC7233239</ArticleId><ArticleId IdType="pubmed">32425269</ArticleId></ArticleIdList></Reference><Reference><Citation>Saha A, Sharma AR, Bhattacharya M, Sharma G, Lee SS, Chakraborty C. Tocilizumab: A Therapeutic Option for the Treatment of Cytokine Storm Syndrome in COVID-19. Arch Med Res (2020) 51(6):595&#x2013;7. doi: 10.1016/j.arcmed.2020.05.009</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.arcmed.2020.05.009</ArticleId><ArticleId IdType="pmc">PMC7241374</ArticleId><ArticleId IdType="pubmed">32482373</ArticleId></ArticleIdList></Reference><Reference><Citation>Hennigan S, Kavanaugh A. Interleukin-6 Inhibitors in the Treatment of Rheumatoid Arthritis. Ther Clin Risk Manage (2008) 4:767&#x2013;75. doi: 10.2147/TCRM.S3470</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/TCRM.S3470</ArticleId><ArticleId IdType="pmc">PMC2621374</ArticleId><ArticleId IdType="pubmed">19209259</ArticleId></ArticleIdList></Reference><Reference><Citation>Brunner HI, Ruperto N, Zuber Z, Keane C, Harari O, Kenwright A, et al. . Efficacy and Safety of Tocilizumab in Patients With Polyarticular-Course Juvenile Idiopathic Arthritis: Results From a Phase 3, Randomised, Double-Blind Withdrawal Trial. Ann Rheumatic Dis (2015) 74(6):1110&#x2013;7. doi: 10.1136/annrheumdis-2014-205351</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2014-205351</ArticleId><ArticleId IdType="pmc">PMC4431348</ArticleId><ArticleId IdType="pubmed">24834925</ArticleId></ArticleIdList></Reference><Reference><Citation>Stone JH, Tuckwell K, Dimonaco S, Klearman M, Aringer M, Blockmans D, et al. . Trial of Tocilizumab in Giant-Cell Arteritis. N Engl J Med (2017) 377(4):317&#x2013;28. doi: 10.1056/NEJMoa1613849</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1613849</ArticleId><ArticleId IdType="pubmed">28745999</ArticleId></ArticleIdList></Reference><Reference><Citation>Tanaka T, Narazaki M, Kishimoto T. Anti-Interleukin-6 Receptor Antibody, Tocilizumab, for the Treatment of Autoimmune Diseases. FEBS Lett (2011) 585:3699&#x2013;709. doi: 10.1016/j.febslet.2011.03.023</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.febslet.2011.03.023</ArticleId><ArticleId IdType="pubmed">21419125</ArticleId></ArticleIdList></Reference><Reference><Citation>
Beneficencia Portuguesa de Sao Paulo . Safety and Efficacy of Tocilizumab in Moderate to Severe COVID-19 With Inflammatory Markers (TOCIBRAS). (2020). (https://clinicaltrials.gov/ct2/show/NCT04403685) [Accessed March 30,2021]</Citation></Reference><Reference><Citation>Luo P, Liu Y, Qiu L, Liu X, Liu D, Li J. Tocilizumab Treatment in COVID-19: A Single Center Experience. J Med Virol (2020) 92(7):814&#x2013;8. doi: 10.1002/jmv.25801</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.25801</ArticleId><ArticleId IdType="pmc">PMC7262125</ArticleId><ArticleId IdType="pubmed">32253759</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu X, Han M, Li T, Sun W, Wang D, Fu B, et al. . Effective Treatment of Severe COVID-19 Patients With Tocilizumab. Proc Natl Acad Sci USA (2020) 117(20):10970&#x2013;5. doi: 10.1073/pnas.2005615117</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.2005615117</ArticleId><ArticleId IdType="pmc">PMC7245089</ArticleId><ArticleId IdType="pubmed">32350134</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosas IO, Br&#xe4;u N, Waters M, Go RC, Hunter BD, Bhagani S, et al. . Tocilizumab in Hospitalized Patients With Severe Covid-19 Pneumonia. N Engl J Med (2021) 384(16):1503&#x2013;16. doi: 10.1056/NEJMc2100217</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMc2100217</ArticleId><ArticleId IdType="pmc">PMC7953459</ArticleId><ArticleId IdType="pubmed">33631066</ArticleId></ArticleIdList></Reference><Reference><Citation>Salama C, Han J, Yau L, Reiss WG, Kramer B, Neidhart JD, et al. . Tocilizumab in Patients Hospitalized With Covid-19 Pneumonia. N Engl J Med (2021) 384(1):20&#x2013;30. doi: 10.1056/NEJMoa2030340</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2030340</ArticleId><ArticleId IdType="pmc">PMC7781101</ArticleId><ArticleId IdType="pubmed">33332779</ArticleId></ArticleIdList></Reference><Reference><Citation>Hermine O, Mariette X, Tharaux PL, Resche-Rigon M, Porcher R, Ravaud P. Effect of Tocilizumab vs Usual Care in Adults Hospitalized With COVID-19 and Moderate or Severe Pneumonia: A Randomized Clinical Trial. JAMA Internal Med (2021) 181(1):144. doi: 10.1001/jamainternmed.2021.2209</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamainternmed.2021.2209</ArticleId><ArticleId IdType="pmc">PMC7577198</ArticleId><ArticleId IdType="pubmed">33080017</ArticleId></ArticleIdList></Reference><Reference><Citation>Salvarani C, Dolci G, Massari M, Merlo DF, Cavuto S, Savoldi L, et al. . Effect of Tocilizumab vs Standard Care on Clinical Worsening in Patients Hospitalized With COVID-19 Pneumonia: A Randomized Clinical Trial. JAMA Internal Med (2021) 181(1):24&#x2013;31. doi: 10.1001/jamainternmed.2021.0404</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamainternmed.2021.0404</ArticleId><ArticleId IdType="pmc">PMC7577199</ArticleId><ArticleId IdType="pubmed">33080005</ArticleId></ArticleIdList></Reference><Reference><Citation>Stone JH, Frigault MJ, Serling-Boyd NJ, Fernandes AD, Harvey L, Foulkes AS, et al. . Efficacy of Tocilizumab in Patients Hospitalized With Covid-19. New Engl J Med (2020) 383(24):2333&#x2013;44. doi: 10.1056/NEJMoa2028836</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2028836</ArticleId><ArticleId IdType="pmc">PMC7646626</ArticleId><ArticleId IdType="pubmed">33085857</ArticleId></ArticleIdList></Reference><Reference><Citation>Kupferschmidt K. World&#x2019;s Largest COVID-19 Drug Trial Identifies Second Compound That Cuts Risk of Death. Science (2021). doi: 10.1126/science.abh0459</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abh0459</ArticleId></ArticleIdList></Reference><Reference><Citation>van Rhee F, Wong RS, Munshi N, Rossi JF, Ke XY, Foss&#xe5; A, et al. . Siltuximab for Multicentric Castleman&#x2019;s Disease: A Randomised, Double-Blind, Placebo-Controlled Trial. Lancet Oncol (2014) 15(9):966&#x2013;74. doi: 10.1016/S1470-2045(14)70319-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1470-2045(14)70319-5</ArticleId><ArticleId IdType="pubmed">25042199</ArticleId></ArticleIdList></Reference><Reference><Citation>Gritti G, Raimondi F, Ripamonti D, Riva I, Landi F, Alborghetti L, et al. . Use of Siltuximab in Patients With COVID-19 Pneumonia Requiring Ventilatory Support. medRxiv (2020). doi: 10.1101/2020.04.01.20048561</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2020.04.01.20048561</ArticleId></ArticleIdList></Reference><Reference><Citation>Fang W, Cai SX, Wang CL, Sun XX, Li K, Yan XW, et al. . Modulation of Mitogen-Activated Protein Kinase Attenuates Sepsis-Induced Acute Lung Injury in Acute Respiratory Distress Syndrome Rats. Mol Med Rep (2017) 16(6):9652&#x2013;8. doi: 10.3892/mmr.2017.7811</Citation><ArticleIdList><ArticleId IdType="doi">10.3892/mmr.2017.7811</ArticleId><ArticleId IdType="pubmed">29039541</ArticleId></ArticleIdList></Reference><Reference><Citation>Ma XL, Kumar S, Gao F, Louden CS, Lopez BL, Christopher TA, et al. . Inhibition of P38 Mitogen-Activated Protein Kinase Decreases Cardiomyocyte Apoptosis and Improves Cardiac Function After Myocardial Ischemia and Reperfusion. Circulation (1999) 99(13):1685&#x2013;91. doi: 10.1161/01.CIR.99.13.1685</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/01.CIR.99.13.1685</ArticleId><ArticleId IdType="pubmed">10190877</ArticleId></ArticleIdList></Reference><Reference><Citation>Zarubin T, Han J. Activation and Signaling of the P38 MAP Kinase Pathway. Cell Res (2005) 15:11&#x2013;8. doi: 10.1038/sj.cr.7290257</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/sj.cr.7290257</ArticleId><ArticleId IdType="pubmed">15686620</ArticleId></ArticleIdList></Reference><Reference><Citation>Bouhaddou M, Memon D, Meyer B, White KM, v RV, Correa Marrero M, et al. . The Global Phosphorylation Landscape of SARS-CoV-2 Infection. Cell (2020) 182(3):685&#x2013;712. doi: 10.1016/j.cell.2020.06.034</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2020.06.034</ArticleId><ArticleId IdType="pmc">PMC7321036</ArticleId><ArticleId IdType="pubmed">32645325</ArticleId></ArticleIdList></Reference><Reference><Citation>Stukalov A, Girault V, Grass V, Karayel O, Bergant V, Urban C, et al. . Multilevel Proteomics Reveals Host Perturbations by SARS-CoV-2 and SARS-CoV. Nature (2021) 594(7862):246&#x2013;52. doi: 10.1038/s41586-021-03493-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-021-03493-4</ArticleId><ArticleId IdType="pubmed">33845483</ArticleId></ArticleIdList></Reference><Reference><Citation>Grimes JM, Grimes KV. P38 MAPK Inhibition: A Promising Therapeutic Approach for COVID-19. J Mol Cell Cardiol (2020) 144:63&#x2013;5. doi: 10.1016/j.yjmcc.2020.05.007</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.yjmcc.2020.05.007</ArticleId><ArticleId IdType="pmc">PMC7228886</ArticleId><ArticleId IdType="pubmed">32422320</ArticleId></ArticleIdList></Reference><Reference><Citation>Babon JJ, Lucet IS, Murphy JM, Nicola NA, Varghese LN. The Molecular Regulation of Janus Kinase (JAK) Activation. Biochem J (2014) 462:1&#x2013;13. doi: 10.1042/BJ20140712</Citation><ArticleIdList><ArticleId IdType="doi">10.1042/BJ20140712</ArticleId><ArticleId IdType="pmc">PMC4112375</ArticleId><ArticleId IdType="pubmed">25057888</ArticleId></ArticleIdList></Reference><Reference><Citation>Renauld JC. Class II Cytokine Receptors and Their Ligands: Key Antiviral and Inflammatory Modulators. Nat Rev Immunol (2003) 3:667&#x2013;76. doi: 10.1038/nri1153</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nri1153</ArticleId><ArticleId IdType="pubmed">12974481</ArticleId></ArticleIdList></Reference><Reference><Citation>Richardson P, Griffin I, Tucker C, Smith D, Oechsle O, Phelan A, et al. . Baricitinib as Potential Treatment for 2019-Ncov Acute Respiratory Disease. Lancet (2020) 395:e30&#x2013;1. doi: 10.1016/S0140-6736(20)30304-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(20)30304-4</ArticleId><ArticleId IdType="pmc">PMC7137985</ArticleId><ArticleId IdType="pubmed">32032529</ArticleId></ArticleIdList></Reference><Reference><Citation>McInnes IB, Byers NL, Higgs RE, Lee J, Macias WL, Na S, et al. . Comparison of Baricitinib, Upadacitinib, and Tofacitinib Mediated Regulation of Cytokine Signaling in Human Leukocyte Subpopulations. Arthritis Res Ther (2019) 21(1):183. doi: 10.1186/s13075-019-1964-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13075-019-1964-1</ArticleId><ArticleId IdType="pmc">PMC6679539</ArticleId><ArticleId IdType="pubmed">31375130</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoang TN, Pino M, Boddapati AK, Viox EG, Starke CE, Upadhyay AA, et al. . Baricitinib Treatment Resolves Lower-Airway Macrophage Inflammation and Neutrophil Recruitment in SARS-CoV-2-Infected Rhesus Macaques. Cell (2021) 184(2):460&#x2013;75. doi: 10.1016/j.cell.2020.11.007</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2020.11.007</ArticleId><ArticleId IdType="pmc">PMC7654323</ArticleId><ArticleId IdType="pubmed">33278358</ArticleId></ArticleIdList></Reference><Reference><Citation>Kalil AC, Patterson TF, Mehta AK, Tomashek KM, Wolfe CR, Ghazaryan V, et al. . Baricitinib Plus Remdesivir for Hospitalized Adults With Covid-19. N Engl J Med (2021) 384(9):795&#x2013;807. doi: 10.1056/NEJMoa2031994</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2031994</ArticleId><ArticleId IdType="pmc">PMC7745180</ArticleId><ArticleId IdType="pubmed">33306283</ArticleId></ArticleIdList></Reference><Reference><Citation>
The U.S. Food and Drug Administration (FDA) . Fact Sheet for Healthcare Providers Emergency Use Authorization (EUA) of Baricitinib [Internet]. Available at: www.lillytrade.com.</Citation></Reference><Reference><Citation>Kucharz EJ, Stajszczyk M, Kotulska-Kucharz A, Batko B, Brzosko M, Jeka S, et al. . Tofacitinib in the Treatment of Patients With Rheumatoid Arthritis: Position Statement of Experts of the Polish Society for Rheumatology. Reumatologia (2018) 56(4):203&#x2013;11. doi: 10.5114/reum.2018.77971</Citation><ArticleIdList><ArticleId IdType="doi">10.5114/reum.2018.77971</ArticleId><ArticleId IdType="pmc">PMC6142023</ArticleId><ArticleId IdType="pubmed">30237624</ArticleId></ArticleIdList></Reference><Reference><Citation>Maslennikov R, Ivashkin V, Vasilieva E, Chipurik M, Semikova P, Semenets V, et al. . Tofacitinib Reduces Mortality in Coronavirus Disease 2019 Tofacitinib in COVID-19. Pulmonary Pharmacol Ther (2021) 69:102039. doi: 10.1016/j.pupt.2021.102039</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.pupt.2021.102039</ArticleId><ArticleId IdType="pmc">PMC8137353</ArticleId><ArticleId IdType="pubmed">34023513</ArticleId></ArticleIdList></Reference><Reference><Citation>Verstovsek S, Mesa RA, Gotlib J, Levy RS, Gupta V, DiPersio JF, et al. . A Double-Blind, Placebo-Controlled Trial of Ruxolitinib for Myelofibrosis. N Engl J Med (2012) 366(9):799&#x2013;807. doi: 10.1056/NEJMoa1110557</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1110557</ArticleId><ArticleId IdType="pmc">PMC4822164</ArticleId><ArticleId IdType="pubmed">22375971</ArticleId></ArticleIdList></Reference><Reference><Citation>la Ros&#xe9;e F, Bremer HC, Gehrke I, Kehr A, Hochhaus A, Birndt S, et al. . The Janus Kinase 1/2 Inhibitor Ruxolitinib in COVID-19 With Severe Systemic Hyperinflammation. Leukemia (2020) 34(7):1805&#x2013;15. doi: 10.1038/s41375-020-0891-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41375-020-0891-0</ArticleId><ArticleId IdType="pmc">PMC7282206</ArticleId><ArticleId IdType="pubmed">32518419</ArticleId></ArticleIdList></Reference><Reference><Citation>Shakoory B, Carcillo JA, Chatham WW, Amdur RL, Zhao H, Dinarello CA, et al. . Interleukin-1 Receptor Blockade Is Associated With Reduced Mortality in Sepsis Patients With Features of Macrophage Activation Syndrome: Reanalysis of a Prior Phase III Trial&#x2217;. Crit Care Med (2016) 44(2):275&#x2013;81. doi: 10.1097/CCM.0000000000001402</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/CCM.0000000000001402</ArticleId><ArticleId IdType="pmc">PMC5378312</ArticleId><ArticleId IdType="pubmed">26584195</ArticleId></ArticleIdList></Reference><Reference><Citation>Kyriazopoulou E, Panagopoulos P, Metallidis S, Dalekos GN, Poulakou G, Gatselis N, et al. . An Open Label Trial of Anakinra to Prevent Respiratory Failure in Covid-19. eLife (2021) 10:e66125. doi: 10.7554/eLife.66125</Citation><ArticleIdList><ArticleId IdType="doi">10.7554/eLife.66125</ArticleId><ArticleId IdType="pmc">PMC8034977</ArticleId><ArticleId IdType="pubmed">33682678</ArticleId></ArticleIdList></Reference><Reference><Citation>Qiu P, Cui X, Sun J, Welsh J, Natanson C, Eichacker PQ. Antitumor Necrosis Factor Therapy is Associated With Improved Survival in Clinical Sepsis Trials: A Meta-Analysis. Crit Care Med (2013) 41:2419&#x2013;29. doi: 10.1097/CCM.0b013e3182982add</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/CCM.0b013e3182982add</ArticleId><ArticleId IdType="pmc">PMC3807639</ArticleId><ArticleId IdType="pubmed">23887234</ArticleId></ArticleIdList></Reference><Reference><Citation>McDermott JE, Mitchell HD, Gralinski LE, Eisfeld AJ, Josset L, Bankhead A, et al. . The Effect of Inhibition of PP1 and Tnf&#x3b1; Signaling on Pathogenesis of SARS Coronavirus. BMC Syst Biol (2016) 10(1):93. doi: 10.1186/s12918-016-0336-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12918-016-0336-6</ArticleId><ArticleId IdType="pmc">PMC5035469</ArticleId><ArticleId IdType="pubmed">27663205</ArticleId></ArticleIdList></Reference><Reference><Citation>Leuschner F, Dutta P, Gorbatov R, Novobrantseva TI, Donahoe JS, Courties G, et al. . Therapeutic siRNA Silencing in Inflammatory Monocytes in Mice. Nat Biotechnol (2011) 29(11):1005&#x2013;10. doi: 10.1038/nbt.1989</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nbt.1989</ArticleId><ArticleId IdType="pmc">PMC3212614</ArticleId><ArticleId IdType="pubmed">21983520</ArticleId></ArticleIdList></Reference><Reference><Citation>Uccelli A, de Rosbo NK. The Immunomodulatory Function of Mesenchymal Stem Cells: Mode of Action and Pathways. Ann New York Acad Sci (2015) 1351(1):114&#x2013;26. doi: 10.1111/nyas.12815</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/nyas.12815</ArticleId><ArticleId IdType="pubmed">26152292</ArticleId></ArticleIdList></Reference><Reference><Citation>Marshall M. The Lasting Misery of Coronavirus Long-Haulers. Nature (2020) 585(7825):339&#x2013;41. doi: 10.1038/d41586-020-02598-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/d41586-020-02598-6</ArticleId><ArticleId IdType="pubmed">32929257</ArticleId></ArticleIdList></Reference><Reference><Citation>Carf&#xec; A, Bernabei R, Landi F, for the Gemelli Against COVID-19 Post-Acute Care Study Group . Persistent Symptoms in Patients After Acute COVID-19. JAMA (2020) 324(6):603&#x2013;5. doi: 10.1001/jama.2020.12603</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2020.12603</ArticleId><ArticleId IdType="pmc">PMC7349096</ArticleId><ArticleId IdType="pubmed">32644129</ArticleId></ArticleIdList></Reference><Reference><Citation>Mandal S, Barnett J, Brill SE, Brown JS, Denneny EK, Hare SS, et al. . Long-Covid&#x2019;: A Cross-Sectional Study of Persisting Symptoms, Biomarker and Imaging Abnormalities Following Hospitalisation for COVID-19. Thorax (2021) 76(4):396&#x2013;8. doi: 10.1136/thoraxjnl-2020-215818</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/thoraxjnl-2020-215818</ArticleId><ArticleId IdType="pmc">PMC7615158</ArticleId><ArticleId IdType="pubmed">33172844</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang C, Huang L, Wang Y, Li X, Ren L, Gu X, et al. . 6-Month Consequences of COVID-19 in Patients Discharged From Hospital: A Cohort Study. Lancet (2021) 397(10270):220&#x2013;32. doi: 10.1016/S0140-6736(20)32656-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(20)32656-8</ArticleId><ArticleId IdType="pmc">PMC7833295</ArticleId><ArticleId IdType="pubmed">33428867</ArticleId></ArticleIdList></Reference><Reference><Citation>Dennis A, Wamil M, Alberts J, Oben J, Cuthbertson DJ, Wootton D, et al. . Multiorgan Impairment in Low-Risk Individuals With Post-COVID-19 Syndrome: A Prospective, Community-Based Study. BMJ Open (2021) 11(3):e048391. doi: 10.1136/bmjopen-2020-048391</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmjopen-2020-048391</ArticleId><ArticleId IdType="pmc">PMC8727683</ArticleId><ArticleId IdType="pubmed">33785495</ArticleId></ArticleIdList></Reference><Reference><Citation>Editorial. Long COVID: Let Patients Help Define Long-Lasting COVID Symptoms. Nature (2020) 586. doi: 10.1038/d41586-020-02796-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/d41586-020-02796-2</ArticleId><ArticleId IdType="pubmed">33029005</ArticleId></ArticleIdList></Reference><Reference><Citation>Callard F, Perego E. How and Why Patients Made Long Covid. Soc Sci Med (2021) 268:113426. doi: 10.1016/j.socscimed.2020.113426</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.socscimed.2020.113426</ArticleId><ArticleId IdType="pmc">PMC7539940</ArticleId><ArticleId IdType="pubmed">33199035</ArticleId></ArticleIdList></Reference><Reference><Citation>Sivan M, Taylor S. NICE Guideline on Long Covid. BMJ (2020). doi: 10.1136/bmj.m4938</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.m4938</ArticleId><ArticleId IdType="pubmed">33361141</ArticleId></ArticleIdList></Reference><Reference><Citation>Venkatesan P. NICE Guideline on Long COVID. Lancet Respir Med (2021) 9(2):129. doi: 10.1016/S2213-2600(21)00031-X</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2213-2600(21)00031-X</ArticleId><ArticleId IdType="pmc">PMC7832375</ArticleId><ArticleId IdType="pubmed">33453162</ArticleId></ArticleIdList></Reference><Reference><Citation>
NIHR. Living With Covid-19. A Dynamic Review of the Evidence Around Ongoing Covid-19 Symptoms (Often Called Long Covid) (https://evidence.nihr.ac.uk/themedreview/living-with-covid19/). Accessed: October 15, 2020. doi: 10.3310/themedreview_41169
</Citation><ArticleIdList><ArticleId IdType="doi">10.3310/themedreview_41169</ArticleId></ArticleIdList></Reference><Reference><Citation>Editorial. Meeting the Challenge of Long COVID. Nat Med (2020) 26. doi: 10.1038/s41591-020-01177-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-020-01177-6</ArticleId><ArticleId IdType="pubmed">33288947</ArticleId></ArticleIdList></Reference><Reference><Citation>Gaebler C, Wang Z, Lorenzi JCC, Muecksch F, Finkin S, Tokuyama M, et al. . Evolution of Antibody Immunity to SARS-CoV-2. Nature (2021) 591(7851):639&#x2013;44. doi: 10.1101/2020.11.03.367391</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2020.11.03.367391</ArticleId><ArticleId IdType="pmc">PMC8221082</ArticleId><ArticleId IdType="pubmed">33461210</ArticleId></ArticleIdList></Reference><Reference><Citation>Dani M, Dirksen A, Taraborrelli P, Torocastro M, Panagopoulos D, Sutton R, et al. . Autonomic Dysfunction in &#x2018;Long COVID&#x2019;: Rationale, Physiology and Management Strategies. Clin Med J R Coll Phys London (2021) 21(1):e63&#x2013;7. doi: 10.7861/clinmed.2020-0896</Citation><ArticleIdList><ArticleId IdType="doi">10.7861/clinmed.2020-0896</ArticleId><ArticleId IdType="pmc">PMC7850225</ArticleId><ArticleId IdType="pubmed">33243837</ArticleId></ArticleIdList></Reference><Reference><Citation>Wallukat G, Hohberger B, Wenzel K, F&#xfc;rst J, Schulze-Rothe S, Wallukat A, et al. . Functional Autoantibodies Against G-Protein Coupled Receptors in Patients With Persistent Long-COVID-19 Symptoms. J Trans Autoimmun (2021) 4:100100. doi: 10.1016/j.jtauto.2021.100100</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jtauto.2021.100100</ArticleId><ArticleId IdType="pmc">PMC8049853</ArticleId><ArticleId IdType="pubmed">33880442</ArticleId></ArticleIdList></Reference><Reference><Citation>Arnold DT, Milne A, Samms E, Stadon L, Maskell NA, Hamilton FW. Are Vaccines Safe in Patients With Long COVID? A Prospective Observational Study. medRxiv (2021). doi: 10.1101/2021.03.11.21253225</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2021.03.11.21253225</ArticleId></ArticleIdList></Reference><Reference><Citation>
LongCovidSOS . The Impact of COVID Vaccination on Symptoms of Long Covid. An International Survey of 900 People With Lived Experience. (2021). (https://www.longcovidsos.org/post/longcovidsos-publish-results-of-their-survey-into-the-impact-of-vaccination-on-long-covid-symptoms) [Accessed May 18,2021].</Citation></Reference><Reference><Citation>Mishra PK, Bruiners N, Ukey R, Datta P, Onyuka A, Handler D, et al. . Vaccination Boosts Protective Responses and Counters SARS-CoV-2-Induced Pathogenic Memory B Cells. medRxiv: Preprint Server Health Sci (2021). doi: 10.1101/2021.04.11.21255153</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2021.04.11.21255153</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>